

UTILITY PATENT APPLICATION TRANSMITTAL

Submit an original and a duplicate for fee processing
(Only for new nonprovisional applications under 37 CFR §1.53(b))

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Attorney Docket No. 175912

First Named Inventor Boyd

Express Mail No. EL190831214US

JC682 U.S. PTO
09/427873

10/27/99

APPLICATION ELEMENTS

1. ☒ Utility Transmittal Form
2. ☒ Specification (including claims and abstract) [Total Pages 59]
3. ☒ Drawings [Total Sheets 8]
4. ☒ Combined Declaration and Power of Attorney [Total Pages 3]
 - a. ☒ Newly executed
 - b. ☐ Copy from prior application
[Note Box 5 below]
 - i. ☐ Deletion of Inventor(s) Signed statement attached deleting inventor(s) named in the prior application
5. ☐ Incorporation by Reference: The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Microfiche Computer Program
7. ☒ Nucleotide and/or Amino Acid Sequence Submission
 - a. ☐ Computer Readable Copy
 - b. ☒ Paper Copy
 - c. ☒ Statement verifying above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet and document(s))
9. ☐ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement (IDS)
☒ Form PTO-1449
☒ Copies of References AA-BA and EZ-GD
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (Should be specifically itemized)
14. ☐ Small Entity Statement(s)
☐ Enclosed
☐ Statement filed in prior application; status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
16. ☒ Other: Submission of Formal Drawings; 12 sheets of formal drawings

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information in (a) and (b) below:

- (a) ☒ Continuation ☐ Divisional ☐ Continuation-in-part of prior application Serial No. 08/969,378.
Prior application information: Examiner Kemmerer; Group Art Unit: 1646
- (b) Preliminary Amendment: Relate Back - 35 USC §120. The Commissioner is requested to amend the specification by inserting the following sentence before the first line:
"This is a ☒ continuation ☐ divisional of copending application(s)
☒ Serial No. 08/969,378, filed on November 13, 1997, which is a divisional of Serial No. 08/429,965, filed on April 27, 1995.
☐ International Application, filed on , and which designates the U.S."

APPLICATION FEES

| BASIC FEE | | | | \$760.00 |
|---|--------------|--------------|-----------|----------|
| CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE | |
| Total Claims | 8 -20= | 0 | x \$18.00 | \$0.00 |
| Independent Claims | 1 - 3= | 0 | x \$78.00 | \$0.00 |
| <input type="checkbox"/> Multiple Dependent Claims(s) if applicable | | | +\$260.00 | \$0.00 |
| Total of above calculations = | | | | \$760.00 |
| Reduction by 50% for filing by small entity = | | | | \$() |
| <input type="checkbox"/> Assignment fee if applicable | | | +\$40.00 | \$ |
| TOTAL = | | | | \$760.00 |


UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. 175912

19. ☐ Please charge my Deposit Account No. 12-1216 in the amount of \$.
20. ☒ A check in the amount of \$760.00 is enclosed.
21. The Commissioner is hereby authorized to credit overpayments or charge any additional fees of the following types to Deposit Account No. 12-1216:
- a. ☒ Fees required under 37 CFR §1.16.
- b. ☒ Fees required under 37 CFR §1.17.
22. ☒ The Commissioner is hereby generally authorized under 37 CFR §1.136(a)(3) to treat any future reply in this or any related application filed pursuant to 37 CFR §1.53 requiring an extension of time as incorporating a request therefor, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 12-1216 for any fee that may be due in connection with such a request for an extension of time.

23. CORRESPONDENCE ADDRESS

Carol Larcher, Registration No. 35,243
Leydig, Voit & Mayer, Ltd.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
Telephone: (312) 616-5600
Facsimile: (312) 616-5700

| | |
|-----------|---|
| Name | Carol Larcher |
| Signature |  |
| Date | October 27, 1999 |

Certificate of Mailing Under 37 CFR §1.10

I hereby certify that this Utility Patent Application Transmittal and all accompanying documents are being deposited with the United States Postal Service "Express Mail Post Office To Addressee" Service under 37 CFR §1.10 on the date indicated below and is addressed to: Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

| | | |
|------------------------|---|------------------|
| Amy Salasche |  | October 27, 1999 |
| Name of Person Signing | Signature | Date |

UTILITY (Rev. 8/30/1999)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Boyd

Group Art Unit: Unassigned

Serial No. Unassigned

Examiner: Unassigned

Filed: July 22, 1999

For: METHODS OF USING
CYANOVIRINS TO INHIBIT VIRAL
INFECTION

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to the examination of this application, please enter the following amendments and consider the following remarks.

AMENDMENTS

IN THE TITLE:

Please change the title to --Methods of Using Cyanovirins to Inhibit Viral Infection--.

IN THE SPECIFICATION:

Page 6, delete lines 15-17.

Page 6, line 18, change "1D" to --1C--.

Page 6, line 21, change "1E" to --1D--.

Page 6, delete lines 26-27.

Page 6, line 29, after "gene" insert --(SEQ ID NOS: 1-4)--.

Page 7, line 23, change "7" to --7A--.

Page 7, line 27, change "8A" to --8--.

Page 7, after line 27, insert the following:

--Figure 7B is a bar graph of % control versus time of addition (hrs) versus % control RT (reverse transcriptase).--.

Page 7, delete lines 31-35, and substitute therefor --

Figure 9 is a flowchart of the synthesis of the DNA sequence as described in Example 2.

094273-1029
E2B22450

Figure 10 is a flowchart of the synthesis of the expression of synthetic cyanovirin genes as described in Example 3.

Figure 11 is a flowchart of the purification of recombinant cyanovirin proteins as described in Example 4.--.

Page 15, line 25, after "cells" insert --)--.

Page 21, line 35, change "8, 9 and 10," to --5A-6D,--.

Page 22, line 5, change "6 and 7)," to --5A-6D),--.

Page 36, line 22, change "1D" to --1C--.

Page 36, line 35, change "1E" to --1D--.

Page 37, lines 1-3, delete "Results from the nonreduced HPLC fractions are shown in Figure 1C and those from the reduced HPLC fractions are shown in Figure 1F."

Page 37, line 17, delete "(as shown in Figure 1C)".

Page 37, line 22, change "1D" to --1C--.

Page 37, line 25, change "1E" to --1D--.

Page 37, line 28, delete "(Figure 1C)".

Page 37, line 31, delete "(Figure 1F)".

Page 38, lines 24-35, change "as follows:" to -- depicted in Figure 9--.

Please delete the flowchart on page 39.

Page 42, line 19, change "individual in the following flow chart" to -- depicted in Figure 10,--.

Please delete the flowchart on page 43.

Page 44, line 36, change "follows:" to -- depicted in Figure 11.--.

Please delete the flowchart on page 45.

Page 46, line 33, change " 1.2×12^5 " to -- 1.2×10^5 --.

Page 50, line 9, change "7" to --7A--.

Page 50, line 17, change "(linegraphs)" to --(Figure 7A)--.

Page 50, line 17, change "inset)" to --Figure 7B)--.

Page 50, line 22, change "7)" to --7B)--.

Page 51, line 3, change "8A" to -- 8--.

Page 51, lines 22 and 23, change "Figure 8B is a" to --A--.

Page 51, line 24, change " , which shows" to --showed--.

IN THE CLAIMS:

Please cancel claims 1-19.

Please add the following new claims:

20. A method of inhibiting therapeutically or prophylactically a viral infection of a host, which method comprises administering to the host an antiviral effective amount of an isolated and purified antiviral agent selected from the group consisting of an antiviral protein, an antiviral peptide, an antiviral protein conjugate, and an antiviral peptide conjugate, wherein said antiviral protein or antiviral peptide is encoded by an isolated and purified nucleic acid molecule encoding at least nine contiguous amino acids of SEQ ID NO: 2, wherein said at least nine contiguous amino acids of SEQ ID NO: 2 has antiviral activity, whereupon administration of said antiviral effective amount of said antiviral agent, said viral infection of said host is inhibited.

21. The method of claim 20, wherein said antiviral protein comprises the amino acid sequence of SEQ ID NO: 2.

22. The method of claim 20, wherein said antiviral protein conjugate or said antiviral peptide conjugate comprises (i) at least nine contiguous amino acids of SEQ ID NO: 2, wherein said at least nine contiguous amino acids of SEQ ID NO: 2 has antiviral activity, and (ii) an isolated and purified viral envelope glycoprotein.

23. The method of claim 22, wherein said antiviral protein comprises the amino acid sequence of SEQ ID NO: 2.

24. The method of claim 22, wherein said isolated and purified viral envelope glycoprotein is an isolated and purified retroviral envelope glycoprotein.

25. The method of claim 24, wherein said isolated and purified retroviral envelope glycoprotein is an isolated and purified immunodeficiency viral envelope glycoprotein.

26. The method of claim 25, wherein said isolated and purified immunodeficiency viral envelope glycoprotein is an isolated and purified viral envelope glycoprotein of HIV-1 or HIV-2.

27. The method of claim 26, wherein said isolated and purified viral envelope glycoprotein of HIV-1 or HIV-2 comprises gp120.

IN THE DRAWINGS:

Please delete Figure 8B and add Figures 9-11 (submitted herewith).

Please delete Figures 1C and 1F and renumber Figures 1D and 1E as Figures 1C and 1D, respectively.

Please renumber Figure 7 as Figures 7A (line graph) and 7B (inset bar graph).

REMARKS

The title has been amended so that it is more descriptive of the claimed invention. The amended title is supported by the specification in its entirety and the claims. Accordingly, the amendment of the title does not introduce new matter.

The specification was amended (i) to change the reference to Figure 8A to Figure 8 on pages 7 and 51 of the specification, (ii) to delete the description of Figure 8B and the flowcharts on pages 39, 43 and 45, (iii) to insert brief descriptions of Figures 9-11 in the section entitled "Brief Description of the Drawings," (iv) to delete reference to Figure 8B on page 51 of the specification, (v) to add references to Figures 9-11 as appropriate in the specification, (vi) to insert sequence identification numbers with respect to Figure 2, (vii) to insert a missing parenthesis, (viii) to correct a typographical error, and (ix) to reflect the cancellation of Figures 1C and 1F and the relabeling of Figures 1D, 1E and 7. Figures 1C and 1F have been cancelled as unnecessary to the understanding and practice of the invention. The content of Figures 1C and 1F is described in the specification at page 37, for example. Figures 1D and 1E, thus, have been relabeled as Figures 1C and 1D, respectively. Figure 7 contains an inset and, therefor, has been relabeled as Figures 7A (line graph) and 7B (inset). The deletion of Figure 8B does not affect the sufficiency of the disclosure inasmuch as what is represented in Figure 8B is described in the specification at page 51, lines 22-26. The addition of Figures 9-11 does not constitute new matter inasmuch as Figures 9-11 correspond to the flowcharts originally set forth on pages 39, 43 and 45, respectively, of the instant specification.


Claims 1-19 have been canceled and claims 20-27 have been added. Claims 20-27 serve to point out more particularly and distinctly claim the subject matter of the present invention as supported by the specification at, for example, page 3, lines 30-33, page 5, lines 8-15, page 5, line 31, through page 6, line 4, page 9, lines 16-22, page 11, line 23, through page 12, line 10, page 12, lines 16-19, page 14, lines 2-7, page 18, lines 16-36, page 20, lines 26-33, page 21, lines 6-15, page 21, line 23, through page 22, line 20 *et seq*, page 26, line 33, through page 27, line 5, page 27, lines 23 *et seq*, and page 28, line 15,

In re Appln. of Boyd
Serial No. Unassigned

through page 35, line 9, and by Examples 1, 4, 5 and 6. Therefore, no new matter has been added by way of these amendments.

The application is considered to be in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



Carol Larcher, Reg. No. 35,243
One of the Attorneys for Applicant
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: October 27, 1999

ANTIVIRAL PROTEINS AND PEPTIDES, DNA CODING
SEQUENCES THEREFOR, AND USES THEREOF

Technical Field of the Invention

This invention relates to antiviral proteins and peptides, collectively referred to as cyanovirins, and conjugates thereof, as well as methods of obtaining
5 antiviral cyanovirins and conjugates thereof, compositions comprising cyanovirins and conjugates thereof, and methods of using cyanovirins and conjugates thereof in clinical applications, such as in antiviral therapy and prophylaxis.

Background of the Invention

Acquired immune deficiency syndrome (AIDS) is a fatal disease, reported cases of which have increased dramatically within the past several years. The AIDS
15 virus was first identified in 1983. It has been known by several names and acronyms. It is the third known T-lymphotropic virus (HTLV-III), and it has the capacity to replicate within cells of the immune system, causing profound cell destruction. The AIDS virus is a
20 retrovirus, a virus that uses reverse transcriptase during replication. This particular retrovirus is also known as lymphadenopathy-associated virus (LAV), AIDS-related virus (ARV) and, most recently, as human immunodeficiency virus (HIV). Two distinct families of
25 HIV have been described to date, namely HIV-1 and HIV-2. The acronym HIV is used herein to refer to human immunodeficiency viruses generically.

HIV exerts profound cytopathic effects on the CD4⁺ helper/inducer T-cells, thereby severely compromising the
30 immune system. HIV infection also results in neurological deterioration and, ultimately, in death of infected individuals. Tens of millions of people are infected with HIV worldwide, and, without effective therapy, most of these are doomed to die. During the
35 long latency, the period of time from initial infection

to the appearance of symptoms, or death, due to AIDS, infected individuals spread the infection further, by sexual contacts, exchanges of contaminated needles during i.v. drug abuse, transfusions of blood or blood products, or maternal transfer of HIV to a fetus or newborn. Thus, there is not only an urgent need for effective therapeutic agents to inhibit the progression of HIV disease in individuals already infected, but also for methods of prevention of the spread of HIV infection from infected individuals to noninfected individuals. Indeed, the World Health Organization (WHO) has assigned an urgent international priority to the search for an effective anti-HIV prophylactic virucide to help curb the further expansion of the AIDS pandemic (Balter, Science 266, 1312-1313, 1994; Merson, Science 260, 1266-1268, 1993; Taylor, J. NIH Res. 6, 26-27, 1994; Rosenberg et al., Sex. Transm. Dis. 20, 41-44, 1993; and Rosenberg, Am. J. Public Health 82, 1473-1478, 1992).

The field of viral therapeutics has developed in response to the need for agents effective against retroviruses, especially HIV. There are many ways in which an agent can exhibit anti-retroviral activity (e.g., see DeClercq, Adv. Virus Res. 42, 1-55, 1993; DeClercq, J. Acquir. Immun. Def. Synd. 4, 207-218, 1991; and Mitsuya et al., Science 249, 1533-1544, 1990). Nucleoside derivatives, such as AZT, which inhibit the viral reverse transcriptase, are the only clinically active agents that are currently available commercially for anti-HIV therapy. Although very useful in some patients, the utility of AZT and related compounds is limited by toxicity and insufficient therapeutic indices for fully adequate therapy. Also, given the recent revelations about the true dynamics of HIV infection (Coffin, Science 267, 483-489, 1995; and Cohen, Science 267, 179, 1995), it is now increasingly apparent that agents acting as early as possible in the viral replicative cycle are needed to inhibit infection of

newly produced, uninfected immune cells generated in the body in response to the virus-induced killing of infected cells. Also, it is essential to neutralize or inhibit new infectious virus produced by infected cells.

5 Therefore, new classes of antiviral agents, to be used alone or in combination with AZT and/or other available antiviral agents, are needed for effective antiviral therapy against AIDS. New agents, which may be used to prevent HIV infection, are also important for
10 prophylaxis. In both areas of need, the ideal new agent(s) would act as early as possible in the viral life cycle; be as virus-specific as possible (i.e., attack a molecular target specific to the virus but not the host); render the intact virus noninfectious; prevent the death
15 or dysfunction of virus-infected cells; prevent further production of virus from infected cells; prevent spread of virus infection to uninfected cells; be highly potent and active against the broadest possible range of strains and isolates of HIV; be resistant to degradation under
20 physiological and rigorous environmental conditions; and be readily and inexpensively produced on a large-scale basis.

Accordingly, it is an object of the present invention to provide antiviral proteins and peptides, and
25 conjugates thereof, which possess the aforementioned particularly advantageous attributes.

It is a related object of the present invention to provide conjugates or chimeras containing an antiviral protein or peptide coupled to an effector molecule.

30 It is still another object of the present invention to provide a composition, in particular a pharmaceutical composition, which inhibits the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.

35 It is another object of the present invention to provide methods of obtaining an antiviral protein or peptide or conjugate thereof.

09427873-102790

It is yet another object of the present invention to provide nucleic acid molecules, including recombinant vectors, encoding such antiviral proteins and peptides and conjugates thereof. A more specific object of the present invention is to provide a DNA coding sequence comprising SEQ ID NO:1.

It is another specific object of the present invention to provide a DNA coding sequence comprising SEQ ID NO:3.

Yet another object of the present invention is to provide a method of using an antiviral protein or peptide to target an effector molecule to virus and/or to virus-producing cells, specifically to retrovirus and/or to retrovirus-producing cells, more specifically to HIV and/or HIV-producing cells, and even more specifically to viral gp120 and/or cell-expressed gp120.

Still yet another object of the present invention is to provide a method of treating an animal, in particular a human, infected by a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-2 or HIV-2. A related object of the present invention is to provide a method of treating an animal, in particular a human, to prevent infection by a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.

It is another related object of the present invention to provide a method of treating inanimate objects, such as medical and laboratory equipment and supplies, to prevent infection of an animal, in particular a human, by a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2. It is a further related object of the present invention to provide a method of treating injectable or infusible fluids, suspensions or solutions, such as blood or blood products, and tissues to prevent infection of an animal, in particular a human, by a

09467873-102799

virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.

These and other objects of the present invention, as well as additional inventive features, will become apparent from the description provided herein.

Brief Summary of the Invention

The present invention provides antiviral agents, in particular antiviral proteins and peptides, collectively referred to as cyanovirins, and conjugates thereof, which are useful for antiviral therapy and prophylaxis. Cyanovirins and conjugates thereof inhibit the infectivity, cytopathicity and replication of a virus, in particular a retrovirus, specifically a human immunodeficiency virus, such as HIV-1 or HIV-2. Also provided are methods of obtaining a cyanovirin and a conjugate thereof. Nucleic acid molecules, including nucleic acid molecules of specified nucleotide sequence and recombinant vectors, encoding cyanovirins and conjugates thereof are also provided. The invention also provides a method of using a cyanovirin to target an effector molecule to a virus, such as a retrovirus, specifically HIV, and/or a virus-producing, such as a retrovirus-producing, specifically HIV-producing, cell, in particular viral gp120 and/or cell-express gp120. The present invention also provides a method of obtaining a substantially pure cyanovirin and a conjugate thereof. The cyanovirin or conjugate thereof can be used in a composition, such as a pharmaceutical composition, which can additionally comprise one or more other antiviral agents. The cyanovirin, conjugate, and composition thereof, alone or in combination with another antiviral agent, therefore, is useful in the therapeutic and prophylactic treatment of an animal, such as a human, infected or at risk for infection with a virus, particularly a retrovirus, specifically a human immunodeficiency virus, such as HIV-1 or HIV-2, and in

the treatment of inanimate objects, such as medical and laboratory equipment and supplies, suspensions or solutions, such as blood and blood products, and tissues to prevent viral infection of an animal, such as a human.

5

Brief Description of the Drawings

Figure 1A is a graph of OD 206 nm versus time (min), which represents an HPLC chromatogram of nonreduced cyanovirin.

10 Figure 1B is a bar graph of maximum dilution for 50% protection versus HPLC fraction, which illustrates the maximum dilution of each HPLC fraction that provided 50% protection from the cytopathic effects of HIV infection for the nonreduced cyanovirin HPLC fractions.

15 Figure 1C is an SDS-polyacrylamide gel electrophoretogram of nonreduced cyanovirin HPLC fractions.

20 Figure 1D is a graph of OD 206 nm versus time (min), which represents an HPLC chromatogram of reduced cyanovirin.

25 Figure 1E is a bar graph of maximum dilution for 50% protection versus HPLC dilution, which illustrates the maximum dilution of each fraction that provided 50% protection from the cytopathic effects of HIV infection for the reduced cyanovirin HPLC fractions.

Figure 1F is an SDS-polyacrylamide gel electrophoretogram of reduced cyanovirin HPLC fractions.

Figure 2 shows an example of a DNA sequence encoding a synthetic cyanovirin gene.

30 Figure 3 illustrates a site-directed mutagenesis maneuver used to eliminate codons for a FLAG octapeptide and a Hind III restriction site from the sequence of Figure 2.

35 Figure 4 shows a typical HPLC chromatogram during the purification of a recombinant native cyanovirin.

09427873-102799

Figure 5A is a graph of % control versus concentration (nm), which illustrates the antiviral activity of native cyanovirin from *Nostoc ellipsosporum*.

Figure 5B is a graph of % control versus concentration (nm), which illustrates the antiviral activity of recombinant cyanovirin.

Figure 5C is a graph of % control versus concentration (nm), which illustrates the antiviral activity of recombinant FLAG-fusion cyanovirin.

Figure 6A is a graph of % control versus concentration (nm), which depicts the relative numbers of viable CEM-SS cells infected with HIV-1 in a BCECF assay.

Figure 6B is a graph of % control versus concentration (nm), which depicts the relative DNA contents of CEM-SS cell cultures infected with HIV-1.

Figure 6C is a graph of % control versus concentration (nm), which depicts the relative numbers of viable CEM-SS cells infected with HIV-1 in an XTT assay.

Figure 6D is a graph of % control versus concentration (nm), which depicts the effect of a range of concentration of cyanovirin upon indices of infectious virus or viral replication.

Figure 7 is a graph of % uninfected control versus time of addition (hrs), which shows results of time-of-addition studies of a cyanovirin, showing anti-HIV activity in CEM-SS cells infected with HIV-1_{RF}.

Figure 8A is a graph of OD (450 nm) versus cyanovirin concentration ($\mu\text{g/ml}$), which illustrates cyanovirin/gp120 interactions defining gp120 as a principal molecular target of cyanovirin.

Figure 8B is a dot blot of binding of cyanovirin and a gp120-HRP conjugate (Invitrogen), which shows that cyanovirin-N specifically bound a horseradish peroxidase conjugate of gp120 (gp120-HRP) in a concentration-dependent manner.

09427873-102799

Detailed Description of the Invention
and Preferred Embodiments

Infection of CD4⁺ cells by HIV-1 and related primate immunodeficiency viruses begins with interaction of the respective viral envelope glycoproteins (generically termed "gp120") with the cell-surface receptor CD4, followed by fusion and entry (Sattentau, AIDS 2, 101-105, 1988; and Koenig et al., PNAS USA 86, 2443-2447, 1989). Productively infected, virus-producing cells express gp120 at the cell surface; interaction of gp120 of infected cells with CD4 on uninfected cells results in formation of dysfunctional multicellular syncytia and further spread of viral infection (Freed et al., Bull. Inst. Pasteur 88, 73, 1990). Thus, the gp120/CD4 interaction is a particularly attractive target for interruption of HIV infection and cytopathogenesis, either by prevention of initial virus-to-cell binding or by blockage of cell-to-cell fusion (Capon et al., Ann. Rev. Immunol. 9, 649-678, 1991). Virus-free or "soluble" gp120 shed from virus or from infected cells in vivo is also an important therapeutic target, since it may otherwise contribute to noninfectious immunopathogenic processes throughout the body, including the central nervous system (Capon et al., 1991, supra; and Lipton, Nature 367, 113-114, 1994). Much vaccine research has focused upon gp120; however, progress has been hampered by hypervariability of the gp120-neutralizing determinants, and consequent extreme strain-dependence of viral sensitivity to gp120-directed antibodies (Berzofsky, J. Acq. Immun. Def. Synd. 4, 451-459, 1991). Relatively little drug discovery and development research has focused specifically upon gp120. A notable exception is the considerable effort that has been devoted to truncated, recombinant "CD4" proteins ("soluble CD4" or "sCD4"), which bind gp120 and inhibit HIV infectivity in vitro (Capon et al., 1991, supra; Schooley et al., Ann. Int. Med. 112, 247-253, 1990; and Husson et al., J. Pediatr. 121, 627-633, 1992). However, clinical

isolates, in contrast to laboratory strains of HIV, have proven highly resistant to neutralization by sCD4 (Orloff et al., AIDS Res. Hum. Retrovir. 11, 335-342, 1995; and Moore et al., J. Virol. 66, 235-243, 1992). Initial
5 clinical trials of sCD4 (Schooley et al., 1990, supra; and Husson et al., 1992, supra), and of sCD4-coupled immunoglobulins (Langner et al., Arch. Virol. 130, 157-170, 1993), and likewise of sCD4-coupled toxins designed to bind and destroy virus-expressing cells (Davey et al.,
10 J. Infect. Dis. 170, 1180-1188, 1994; and Ramachandran et al., J. Infect. Dis. 170, 1009-1113, 1994), have been disappointing. Newer gene-therapy approaches to generating sCD4 directly in vivo (Morgan et al., AIDS Res. Hum. Retrovir. 10, 1507-1515, 1994) will likely
15 suffer similar frustrations.

In view of the above, the principal overall objective of the present invention is to provide anti-viral proteins, peptides and derivatives thereof, and broad medical uses thereof, including prophylactic and/or
20 therapeutic applications against viruses, such as retroviruses, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.

An initial observation, which led to the present invention, was antiviral activity in certain extracts
25 from cultured cyanobacteria (blue-green algae) tested in an anti-HIV screen. The screen is one that was conceived in 1986 (by M.R. Boyd of the National Institutes of Health) and has been developed and operated at the U.S. National Cancer Institute (NCI) since 1988 (see Boyd, in
30 AIDS, Etiology, Diagnosis, Treatment and Prevention, DeVita et al., eds., Philadelphia: Lippincott, 1988, pp. 305-317).

Cyanobacteria (blue-green algae) were specifically chosen for anti-HIV screening because they had been known
35 to produce a wide variety of structurally unique and biologically active non-nitrogenous and amino acid-derived natural products (Faulkner, Nat. Prod. Rep. 11,

09427873 102799

- 355-394, 1994; and Glombitza et al., in Algal and Cyanobacterial Biotechnology, Cresswell, R.C., et al. eds., 1989, pp. 211-218). These photosynthetic procaryotic organisms are significant producers of cyclic and linear peptides (molecular weight generally <3 kDa), which often exhibit hepatotoxic or antimicrobial properties (Okino et al., Tetrahedron Lett. 34, 501-504, 1993; Krishnamurthy et al., PNAS USA 86, 770-774, 1989; Sivonen et al., Chem. Res. Toxicol. 5, 464-469, 1992; Carter et al., J. Org. Chem. 49, 236-241, 1984; and Frankmolle et al., J. Antibiot. 45, 1451-1457, 1992). Sequencing studies of higher molecular weight cyanobacterial peptides and proteins have generally focused on those associated with primary metabolic processes or ones that can serve as phylogenetic markers (Suter et al., FEBS Lett. 217, 279-282, 1987; Rumbeli et al., FEBS Lett. 221, 1-2, 1987; Swanson et al., J. Biol. Chem. 267, 16146-16154, 1992; Michalowski et al., Nucleic Acids Res. 18, 2186, 1990; Sherman et al., in The Cyanobacteria, Fay et al., eds., Elsevier: New York, 1987, pp. 1-33; and Rogers, in The Cyanobacteria, Fay et al., eds., Elsevier: New York, 1987, pp. 35-67). In general, proteins with antiviral properties have not been associated with cyanobacterial sources.
- 25 The cyanobacterial extract leading to the present invention was among many thousands of different extracts initially selected randomly and tested blindly in the anti-HIV screen described above. A number of these extracts had been determined preliminarily to show anti-HIV activity in the NCI screen (Patterson et al., J. Phycol. 29, 125-130, 1993). From this group, an aqueous extract from *Nostoc ellipsosporum*, which had been prepared as described (Patterson, 1993, supra) and which showed an unusually high anti-HIV potency and in vitro "therapeutic index" in the NCI primary screen, was selected for detailed investigation. A specific

09127873-102799

bioassay-guided strategy was used to isolate and purify a homogenous protein highly active against HIV.

5 In the bioassay-guided strategy, initial selection of the extract for fractionation, as well as the decisions concerning the overall chemical isolation method to be applied, and the nature of the individual steps therein, were determined by interpretation of biological testing data. The anti-HIV screening assay (e.g., see Boyd, 1988, supra; Weislow et al., J. Natl. Cancer Inst. 81, 577-586, 1989), which was used to guide the isolation and purification process, measures the degree of protection of human T-lymphoblastoid cells from the cytopathic effects of HIV. Fractions of the extract of interest are prepared using a variety of chemical means and are tested blindly in the primary screen. Active fractions are separated further, and the resulting subfractions are likewise tested blindly in the screen. This process is repeated as many times as necessary in order to obtain the active compound(s), i.e., antiviral fraction(s) representing pure compound(s), which then can be subjected to detailed chemical analysis and structural elucidation.

Using this strategy, aqueous extracts of *Nostoc ellipsosporum* were shown to contain an antiviral protein. Accordingly, the present invention provides an isolated and purified antiviral protein, named cyanovirin-N, from *Nostoc ellipsosporum*. Herein the term "cyanovirin" is used generically to refer to a native cyanovirin or any related, functionally equivalent protein, peptide or derivative thereof. By definition, in this context, a related, functionally equivalent protein, peptide or derivative thereof a) contains a sequence of at least nine amino acids directly homologous with any sub-sequence of nine contiguous amino acids contained within a native cyanovirin, and, b) is capable of specifically binding to virus, more specifically a primate immunodeficiency virus, more specifically HIV-1, HIV-2 or

SIV, or to an infected host cell expressing one or more viral antigen(s), more specifically an envelope glycoprotein, such as gp120, of the respective virus. Herein, the term "protein" refers to a sequence

5 comprising 100 or more amino acids, whereas "peptide" refers to a sequence comprising less than 100 amino acids. Preferably, the protein, peptide or derivative thereof comprises an amino acid sequence that is substantially homologous to that of an antiviral protein
10 from *Nostoc ellipsosporum*. By "substantially homologous" is meant sufficient homology to render the protein, peptide or derivative thereof antiviral, with antiviral activity characteristic of an antiviral protein isolated from *Nostoc ellipsosporum*. At least about 50% homology,
15 preferably at least about 75% homology, and most preferably at least about 90% homology should exist. A cyanovirin conjugate comprises a cyanovirin coupled to one or more selected effector molecule(s), such as a toxin or immunological reagent. "Immunological reagent"
20 will be used to refer to an antibody, an immunoglobulin, and an immunological recognition element. An immunological recognition element is an element, such as a peptide, e.g., the FLAG sequence of the recombinant cyanovirin-FLAG fusion protein, which facilitates,
25 through immunological recognition, isolation and/or purification and/or analysis of the protein or peptide to which it is attached. A cyanovirin fusion protein is a type of cyanovirin conjugate, wherein a cyanovirin is coupled to one or more other protein(s) having any
30 desired properties or effector functions, such as cytotoxic or immunological properties, or other desired properties, such as to facilitate isolation, purification or analysis of the fusion protein.

Accordingly, the present invention provides an
35 isolated and purified protein encoded by a nucleic acid molecule comprising a sequence of SEQ ID NO:1, a nucleic acid molecule comprising a sequence of SEQ ID NO:3, a

09427873.102799

nucleic acid molecule encoding an amino acid sequence of SEQ ID NO:2, or a nucleic acid molecule encoding an amino acid sequence of SEQ ID NO:4. Preferably, the
5 nine contiguous amino acids of the amino acid sequence of SEQ ID NO:2.

The present invention also provides a method of obtaining a cyanovirin from *Nostoc ellipsosporum*. Such a method comprises (a) identifying an extract of *Nostoc*
10 *ellipsosporum* containing antiviral activity, (b) optionally removing high molecular weight biopolymers from the extract, (c) antiviral bioassay-guided fractionating the extract to obtain a crude extract of cyanovirin, and (d) purifying the crude extract by
15 reverse-phase HPLC to obtain cyanovirin (see, also, Example 1). More specifically, the method involves the use of ethanol to remove high molecular weight biopolymers from the extract and the use of an anti-HIV bioassay to guide fractionation of the extract.

20 Cyanovirin-N, which was isolated and purified using the aforementioned method, was subjected to conventional procedures typically used to determine the amino acid sequence of a given pure protein. Thus, the cyanovirin was initially sequenced by N-terminal Edman degradation
25 of intact protein and numerous overlapping peptide fragments generated by endoprotease digestion. Amino acid analysis was in agreement with the deduced sequence. ESI mass spectrometry of reduced, HPLC-purified cyanovirin-N showed a molecular ion consistent with the
30 calculated value. These studies indicated that cyanovirin-N from *Nostoc ellipsosporum* was comprised of a unique sequence of 101 amino acids having little or no significant homology to previously described proteins or transcription products of known nucleotide sequences. No
35 more than eight contiguous amino acids from cyanovirin were found in any amino acid sequences from known proteins, nor were there any known proteins from any

09427873-102799

source containing greater than 13% sequence homology with cyanovirin-N. Given the chemically deduced amino acid sequence of cyanovirin-N, a corresponding recombinant cyanovirin-N (r-cyanovirin-N) was created and used to
5 definitively establish that the deduced amino acid sequence was, indeed, active against virus, such as HIV (Boyd et al., 1995, supra; also, see Examples 2-5).

Accordingly, the present invention provides isolated and purified nucleic acid molecules and synthetic nucleic
10 acid molecules, which comprise a coding sequence for a cyanovirin, such as an isolated and purified nucleic acid molecule comprising a sequence of SEQ ID NO:1, an isolated and purified nucleic acid molecule comprising a sequence of SEQ ID NO:3, an isolated and purified nucleic
15 acid molecule encoding an amino acid sequence of SEQ ID NO:2, an isolated and purified nucleic acid molecule encoding an amino acid sequence of SEQ ID NO:4, and a nucleic acid molecule that is substantially homologous to any one or more of the aforementioned nucleic acid
20 molecules. By "substantially homologous" is meant sufficient homology to render the protein, peptide or derivative thereof antiviral, with antiviral activity characteristic of an antiviral protein isolated from *Nostoc ellipsosporum*. At least about 50% homology, preferably at least about 75% homology, and most
25 preferably at least about 90% homology should exist. More specifically, the present invention provides one of the aforementioned nucleic acid molecules, which comprises a nucleic acid sequence encoding at least nine
30 contiguous amino acids of the amino acid sequence of SEQ ID NO:2.

Given the present disclosure, it will be apparent to one skilled in the art that a partial cyanovirin-N gene codon sequence will likely suffice to code for a fully
35 functional, i.e., antiviral, such as anti-HIV, cyanovirin. A minimum essential DNA coding sequence(s) for a functional cyanovirin can readily be determined by

09427873-102799

one skilled in the art, for example, by synthesis and evaluation of sub-sequences comprising the native cyanovirin, and by site-directed mutagenesis studies of the cyanovirin-N DNA coding sequence.

- 5 Using an appropriate DNA coding sequence, a recombinant cyanovirin can be made by genetic engineering techniques (for general background see, e.g., Nicholl, in An Introduction to Genetic Engineering, Cambridge University Press: Cambridge, 1994, pp. 1-5 & 127-130;
- 10 Steinberg et al., in Recombinant DNA Technology Concepts and Biomedical Applications, Prentice Hall: Englewood Cliffs, NJ, 1993, pp. 81-124 & 150-162; Sofer in Introduction to Genetic Engineering, Butterworth-Heinemann, Stoneham, MA, 1991, pp. 1-21 & 103-126; Old et
- 15 al., in Principles of Gene Manipulation, Blackwell Scientific Publishers: London, 1992, pp. 1-13 & 108-221; and Emtage, in Delivery Systems for Peptide Drugs, Davis et al., eds., Plenum Press: New York, 1986, pp. 23-33). For example, a *Nostoc ellipsosporum* gene or cDNA encoding
- 20 a cyanovirin can be identified and subcloned. The gene or cDNA can then be incorporated into an appropriate expression vector and delivered into an appropriate protein-synthesizing organism (e.g., *E. coli*, *S. cerevisiae*, *P. pastoris*, or other bacterial, yeast,
- 25 insect or mammalian cells), where the gene, under the control of an endogenous or exogenous promoter, can be appropriately transcribed and translated. Such
- 30 expression vectors (including, but not limited to, phage, cosmid, viral, and plasmid vectors) are known to those skilled in the art, as are reagents and techniques
- 35 appropriate for gene transfer (e.g., transfection, electroporation, transduction, micro-injection, transformation, etc.). Subsequently, the recombinantly produced protein can be isolated and purified using
- standard techniques known in the art (e.g., chromatography, centrifugation, differential solubility,

09427873-10299
652207-282460

isoelectric focusing, etc.), and assayed for antiviral activity.

Alternatively, a native cyanovirin can be obtained from *Nostoc ellipsosporum* by non-recombinant methods (e.g., see Example 1 and above), and sequenced by conventional techniques. The sequence can then be used to synthesize the corresponding DNA, which can be subcloned into an appropriate expression vector and delivered into a protein-producing cell for *en mass* recombinant production of the desired protein.

In this regard, the present invention also provides a vector comprising a DNA sequence, e.g., a *Nostoc ellipsosporum* gene sequence for cyanovirin, a cDNA encoding a cyanovirin, or a synthetic DNA sequence encoding cyanovirin, a host cell comprising the vector, and a method of using such a host cell to produce a cyanovirin.

The DNA, whether isolated and purified or synthetic, or cDNA encoding a cyanovirin can encode for either the entire cyanovirin or a portion thereof. Where the DNA or cDNA does not comprise the entire coding sequence of the native cyanovirin, the DNA or cDNA can be subcloned as part of a gene fusion. In a transcriptional gene fusion, the DNA or cDNA will contain its own control sequence directing appropriate production of protein (e.g., ribosome binding site, translation initiation codon, etc.), and the transcriptional control sequences (e.g., promoter elements and/or enhancers) will be provided by the vector. In a translational gene fusion, transcriptional control sequences as well as at least some of the translational control sequences (i.e., the translational initiation codon) will be provided by the vector. In the case of a translational gene fusion, a chimeric protein will be produced.

Genes also can be constructed for specific fusion proteins containing a functional cyanovirin component plus a fusion component conferring additional desired

09427873.102799

attribute(s) to the composite protein. For example, a fusion sequence for a toxin or immunological reagent, as defined above, can be added to facilitate purification and analysis of the functional protein (e.g., such as the
5 FLAG-cyanovirin-N fusion protein detailed within Examples 2-5).

Genes can be specifically constructed to code for fusion proteins, which contain a cyanovirin coupled to an effector protein, such as a toxin or immunological
10 reagent, for specific targeting to viral-infected, e.g., HIV and/or HIV-infected, cells. In these instances, the cyanovirin moiety serves not only as a neutralizing agent but also as a targeting agent to direct the effector activities of these molecules selectively against a given
15 virus, such as HIV. Thus, for example, a therapeutic agent can be obtained by combining the HIV-targeting function of a functional cyanovirin with a toxin aimed at neutralizing infectious virus and/or by destroying cells producing infectious virus, such as HIV. Similarly, a
20 therapeutic agent can be obtained, which combines the viral-targeting function of a cyanovirin with the multivalency and effector functions of various immunoglobulin subclasses.

Similar rationales underlie extensive developmental
25 therapeutic efforts exploiting the HIV gp120-targeting properties of sCD4. For example, sCD4-toxin conjugates have been prepared in which sCD4 is coupled to a *Pseudomonas* exotoxin component (Chaudhary et al., in The Human Retrovirus, Gallo et al., eds., Academic Press: San
30 Diego, 1991, pp. 379-387; and Chaudhary et al., Nature 335, 369-372, 1988), or to a diphtheria toxin component (Aullo et al., EMBO J. 11, 575-583, 1992) or to a ricin A-chain component (Till et al., Science 242, 1166-1167, 1988). Likewise, sCD4-immunoglobulin conjugates have
35 been prepared in attempts to decrease the rate of *in vivo* clearance of functional sCD4 activity, to enhance placental transfer, and to effect a targeted recruitment

09407873-102990

of immunological mechanisms of pathogen elimination, such as phagocytic engulfment and killing by antibody-dependent cell-mediated cytotoxicity, to kill and/or remove HIV-infected cells and virus (Capon et al., Nature 337, 525-531, 1989; Trauneker et al., Nature 339, 68-70, 1989; and Langner et al., 1993, supra). While such CD4-immunoglobulin conjugates (sometimes called "immunoadhesins") have, indeed, shown advantageous pharmacokinetic and distributional attributes *in vivo*, and anti-HIV effects *in vitro*, clinical results have been discouraging (Schooley et al., 1990, supra; Husson et al., 1992, supra; and Langner et al., 1993, supra). This is not surprising since clinical isolates of HIV, as opposed to laboratory strains, are highly resistant to binding and neutralization by sCD4 (Orloff et al., 1995, supra; and Moore et al., 1992, supra). Therefore, the extraordinarily broad targeting properties of a functional cyanovirin to viruses, e.g., primate retroviruses, in general, and clinical and laboratory strains, in particular (Boyd et al., 1995, supra; and Gustafson et al., 1995, supra), can be especially advantageous for combining with toxins, immunoglobulins and other selected effector proteins.

Viral-targeted conjugates can be prepared either by genetic engineering techniques (see, for example, Chaudhary et al., 1988, supra) or by chemical coupling of the targeting component with an effector component. The most feasible or appropriate technique to be used to construct a given cyanovirin conjugate or fusion protein will be selected based upon consideration of the characteristics of the particular effector molecule selected for coupling to a cyanovirin. For example, with a selected non-proteinaceous effector molecule, chemical coupling, rather than genetic engineering techniques, may be the only feasible option for creating the desired cyanovirin conjugate.

Accordingly, the present invention also provides nucleic acid molecules encoding cyanovirin fusion proteins. In particular, the present invention provides a nucleic acid molecule comprising SEQ ID NO:3 and
5 substantially homologous sequences thereof. Also provided is a vector comprising a nucleic acid sequence encoding a cyanovirin fusion protein and a method of obtaining a cyanovirin fusion protein by expression of the vector encoding a cyanovirin fusion protein in a
10 protein-synthesizing organism as described above. Accordingly, cyanovirin fusion proteins are also provided.

In view of the above, the present invention further provides an isolated and purified nucleic acid molecule,
15 which comprises a cyanovirin coding sequence, such as one of the aforementioned nucleic acids, namely a nucleic acid molecule encoding an amino acid sequence of SEQ ID NO:2, a nucleic acid molecule encoding an amino acid sequence of SEQ ID NO:4, a nucleic acid molecule
20 comprising a sequence of SEQ ID NO:1, or a nucleic acid molecule comprising a sequence of SEQ ID NO:3, coupled to a second nucleic acid encoding an effector protein. The first nucleic acid preferably comprises a nucleic acid sequence encoding at least nine contiguous amino acids of
25 the amino acid sequence of SEQ ID NO:2, which encodes a functional cyanovirin, and the second nucleic acid preferably encodes an effector protein, such as a toxin or immunological reagent as described above.

Accordingly, the present invention also further
30 provides an isolated and purified protein encoded by a nucleic acid molecule comprising a sequence of SEQ ID NO:1, a nucleic acid molecule comprising a sequence of SEQ ID NO:3, a nucleic acid molecule encoding an amino acid sequence of SEQ ID NO:2, or a nucleic acid molecule
35 encoding an amino acid sequence of SEQ ID NO:4. Preferably, the aforementioned nucleic acid molecules encode at least nine contiguous amino acids of the amino

09427873.102789

acid sequence of SEQ ID NO:2 coupled to an effector molecule, such as a toxin or immunological reagent as described above. Preferably, the effector molecule targets a virus, more preferably HIV, and, most preferably glycoprotein gp120. The coupling can be effected at the DNA level or by chemical coupling as described above. For example, a cyanovirin-effector protein conjugate of the present invention can be obtained by (a) selecting a desired effector protein or peptide; (b) synthesizing a composite DNA coding sequence comprising a first DNA coding sequence comprising one of the aforementioned nucleic acid sequences, which codes for a functional cyanovirin, coupled to a second DNA coding sequence for an effector protein or peptide, e.g., a toxin or immunological reagent; (c) expressing said composite DNA coding sequence in an appropriate protein-synthesizing organism; and (d) purifying the desired fusion protein or peptide to substantially pure form. Alternatively, a cyanovirin-effector molecule conjugate of the present invention can be obtained by (a) selecting a desired effector molecule and a cyanovirin or cyanovirin fusion protein; (b) chemically coupling the cyanovirin or cyanovirin fusion protein to the effector molecule; and (c) purifying the desired cyanovirin-effector molecule conjugate to substantially pure form.

Conjugates containing a functional cyanovirin coupled to a desired effector component, such as a toxin, immunological reagent, or other functional reagent, can be designed even more specifically to exploit the unique gp120-targeting properties of cyanovirins. Example 6 reveals novel gp120-directed effects of cyanovirins. Additional insights were gained from solid-phase ELISA experiments (Boyd et al., 1995, *supra*). Both C-terminal gp120-epitope-specific capture or CD4-receptor capture of gp120, when detected either with polyclonal HIV-1-Ig or with mouse MAb to the immunodominant, third hypervariable (V3) epitope (Matsushita et al., *J. Virol.* 62, 2107-2114,

094427873 102799

1988), were strikingly inhibited by cyanovirin.

Generally, engagement of the CD4 receptor does not interfere with antibody recognition of the V3 epitope, and vice versa (Moore et al., AIDS Res. Hum. Retrovir. 4, 369-379, 1988; and Matsushita et al., 1988, supra).

However, cyanovirin apparently is capable of more global conformational effects on gp120, as evidenced by loss of immunoreactivity at multiple, distinct, non-overlapping epitopes. The range of antiviral activity (Boyd et al., 1995, supra) of cyanovirin against diverse CD4⁺-tropic immunodeficiency virus strains in various target cells is remarkable; all tested strains of HIV-1, HIV-2 and SIV were similarly sensitive to cyanovirin; clinical isolates and laboratory strains showed essentially equivalent sensitivity. Cocultivation of chronically infected and uninfected CEM-SS cells with cyanovirin did not inhibit viral replication, but did cause a concentration-dependent inhibition of cell-to-cell fusion and virus transmission; similar results from binding and fusion inhibition assays employing HeLa-CD4-LTR- β -galactosidase cells were consistent with cyanovirin inhibition of virus-cell and/or cell-cell binding.

The anti-viral, e.g., anti-HIV, activity of the cyanovirins and conjugates thereof of the present invention can be further demonstrated in a series of interrelated in vitro antiviral assays (Gulakowski et al., J. Virol. Methods 33, 87-100, 1991), which accurately predict for antiviral activity in humans. These assays measure the ability of compounds to prevent the replication of HIV and/or the cytopathic effects of HIV on human target cells. These measurements directly correlate with the pathogenesis of HIV-induced disease in vivo. The results of the analysis of the antiviral activity of cyanovirins or conjugates, as set forth in Example 5 and as illustrated in Figures 8, 9 and 10, are believed to predict accurately the antiviral activity of these products in vivo in humans and, therefore,

00427873-102798

establish the utility of the present invention.

Furthermore, since the present invention also provides methods of ex vivo use of cyanovirins and conjugates (e.g., see results set forth in Example 5, and in Figures 6 and 7), the utility of cyanovirins and conjugates thereof is even more certain.

The cyanovirins and conjugates thereof of the present invention can be shown to inhibit a virus, specifically a retrovirus, such as the human immunodeficiency virus, i.e., HIV-1 or HIV-2. The cyanovirins and conjugates of the present invention could be used to inhibit other retroviruses as well as other viruses. Examples of viruses that may be treated in accordance with the present invention include, but are not limited to, Type C and Type D retroviruses, HTLV-1, HTLV-2, HIV, FLV, SIV, MLV, BLV, BIV, equine infectious virus, anemia virus, avian sarcoma viruses, such as Rous sarcoma virus (RSV), hepatitis type A, B, non-A and non-B viruses, arboviruses, varicella viruses, measles, mumps and rubella viruses.

Cyanovirins and conjugates thereof collectively comprise proteins and peptides, and, as such, are particularly susceptible to hydrolysis of amide bonds (e.g., catalyzed by peptidases) and disruption of essential disulfide bonds or formation of inactivating or unwanted disulfide linkages (Carone et al., J. Lab. Clin. Med. 100, 1-14, 1982). There are various ways to alter molecular structure, if necessary, to provide enhanced stability to the cyanovirin or conjugate thereof (Wunsch, Biopolymers 22, 493-505, 1983; and Samanen, in Polymeric Materials in Medication, Gebelein et al., eds., Plenum Press: New York, 1985, pp. 227-242), which may be essential for preparation and use of pharmaceutical compositions containing cyanovirins or conjugates thereof for therapeutic or prophylactic applications against viruses, e.g., HIV. Possible options for useful chemical modifications of a cyanovirin or conjugate include, but

are not limited to, the following (adapted from Samanen, J.M., 1985, supra): (a) olefin substitution, (b) carbonyl reduction, (c) D-amino acid substitution, (d) N α -methyl substitution, (e) C α -methyl substitution, (f) C α -C'-methylene insertion, (g) dehydro amino acid insertion, (h) retro-inverso modification, (i) N-terminal to C-terminal cyclization, and (j) thiomethylene modification. Cyanovirins and conjugates thereof also can be modified by covalent attachment of carbohydrate and polyoxyethylene derivatives, which are expected to enhance stability and resistance to proteolysis (Abuchowski et al., in Enzymes as Drugs, Holcenberg et al., eds., John Wiley: New York, 1981, pp. 367-378).

Other important general considerations for design of delivery strategy systems and compositions, and for routes of administration, for protein and peptide drugs, such as cyanovirins and conjugates thereof (Eppstein, CRC Crit. Rev. Therapeutic Drug Carrier Systems 5, 99-139, 1988; Siddiqui et al., CRC Crit. Rev. Therapeutic Drug Carrier Systems 3, 195-208, 1987); Banga et al., Int. J. Pharmaceutics 48, 15-50, 1988; Sanders, Eur. J. Drug Metab. Pharmacokinetics 15, 95-102, 1990; and Verhoef, Eur. J. Drug Metab. Pharmacokinetics 15, 83-93, 1990), also apply. The appropriate delivery system for a given cyanovirin or conjugate thereof will depend upon its particular nature, the particular clinical application, and the site of drug action. As with any protein or peptide drug, oral delivery of a cyanovirin or a conjugate thereof will likely present special problems, due primarily to instability in the gastrointestinal tract and poor absorption and bioavailability of intact, bioactive drug therefrom. Therefore, especially in the case of oral delivery, but also possibly in conjunction with other routes of delivery, it will be necessary to use an absorption-enhancing agent in combination with a given cyanovirin or conjugate thereof. A wide variety of absorption-enhancing agents have been investigated and/or

applied in combination with protein and peptide drugs for oral delivery and for delivery by other routes (Verhoef, 1990, supra; van Hoogdalem, Pharmac. Ther. 44, 407-443, 1989; Davis, J. Pharm. Pharmacol. 44(Suppl. 1), 186-190, 1992). Most commonly, typical enhancers fall into the general categories of (a) chelators, such as EDTA, salicylates, and N-acyl derivatives of collagen, (b) surfactants, such as lauryl sulfate and polyoxyethylene-9-lauryl ether, (c) bile salts, such as glycholate and taurocholate, and derivatives, such as taurodihydrofusidate, (d) fatty acids, such as oleic acid and capric acid, and their derivatives, such as acylcarnitines, monoglycerides and diglycerides, (e) non-surfactants, such as unsaturated cyclic ureas, (f) saponins, (g) cyclodextrins, and (h) phospholipids.

Other approaches to enhancing oral delivery of protein and peptide drugs, such as the cyanovirins and conjugates thereof, can include aforementioned chemical modifications to enhance stability to gastrointestinal enzymes and/or increased lipophilicity. Alternatively, or in addition, the protein or peptide drug can be administered in combination with other drugs or substances, which directly inhibit proteases and/or other potential sources of enzymatic degradation of proteins and peptides. Yet another alternative approach to prevent or delay gastrointestinal absorption of protein or peptide drugs, such as cyanovirins or conjugates, is to incorporate them into a delivery system that is designed to protect the protein or peptide from contact with the proteolytic enzymes in the intestinal lumen and to release the intact protein or peptide only upon reaching an area favorable for its absorption. A more specific example of this strategy is the use of biodegradable microcapsules or microspheres, both to protect vulnerable drugs from degradation, as well as to effect a prolonged release of active drug (Deasy, in Microencapsulation and Related Processes, Swarbrick, ed.,

Marcell Dekker, Inc.: New York, 1984, pp. 1-60, 88-89, 208-211). Microcapsules also can provide a useful way to effect a prolonged delivery of a protein and peptide drug, such as a cyanovirin or conjugate thereof, after
5 injection (Maulding, J. Controlled Release 6, 167-176, 1987).

Given the aforementioned potential complexities of successful oral delivery of a protein or peptide drug, it is fortunate that there are numerous other potential
10 routes of delivery of a protein or peptide drug, such as a cyanovirin or conjugate thereof. These routes include intravenous, intraarterial, intrathecal, intracisternal, buccal, rectal, nasal, pulmonary, transdermal, vaginal, ocular, and the like (Eppstein, 1988, supra; Siddiqui et al., 1987, supra; Banga et al., 1988, supra; Sanders, 1990, supra; Verhoef, 1990, supra; Barry, in Delivery Systems for Peptide Drugs, Davis et al., eds., Plenum Press: New York, 1986, pp. 265-275; and Patton et al., Adv. Drug Delivery Rev. 8, 179-196, 1992). With any of
15 these routes, or, indeed, with any other route of administration or application, a protein or peptide drug, such as a cyanovirin or conjugate thereof, may initiate an immunogenic reaction. In such situations it may be necessary to modify the molecule in order to mask
20 immunogenic groups. It also can be possible to protect against undesired immune responses by judicious choice of method of formulation and/or administration. For example, site-specific delivery can be employed, as well as masking of recognition sites from the immune system by
25 use or attachment of a so-called tolerogen, such as polyethylene glycol, dextran, albumin, and the like (Abuchowski et al., 1981, supra; Abuchowski et al., J. Biol. Chem. 252, 3578-3581, 1977; Lisi et al., J. Appl. Biochem. 4, 19-33, 1982; and Wileman et al., J. Pharm. Pharmacol. 38, 264-271, 1986). Such modifications also
30 can have advantageous effects on stability and half-life both in vivo and ex vivo. Other strategies to avoid

1562207 2482460

untoward immune reactions can also include the induction of tolerance by administration initially of only low doses. In any event, it will be apparent from the present disclosure to one skilled in the art that for any particular desired medical application or use of a cyanovirin or conjugate thereof, the skilled artisan can select from any of a wide variety of possible compositions, routes of administration, or sites of application, what is advantageous.

Accordingly, the antiviral cyanovirins and conjugates thereof of the present invention can be formulated into various compositions for use either in therapeutic treatment methods for infected individuals, or in prophylactic methods against viral, e.g., HIV, infection of uninfected individuals.

The present invention also provides a pharmaceutical composition, which comprises an antiviral effective amount of an isolated and purified cyanovirin or cyanovirin conjugate and a pharmaceutically acceptable carrier. The composition can further comprise an antiviral effective amount of at least one additional antiviral compound other than a cyanovirin or conjugate thereof. Suitable antiviral compounds include AZT, ddI, ddC, gancyclovir, fluorinated dideoxynucleosides, nevirapine, R82913, Ro 31-8959, BI-RJ-70, acyclovir, α -interferon, recombinant SCD4, michellamines, calanolides, nonoxynol-9, gossypol and derivatives thereof, and gramicidin. The cyanovirin used in the pharmaceutical composition can be isolated and purified from nature or genetically engineered. Similarly, the cyanovirin conjugate can be genetically engineered or chemically coupled.

The present inventive compositions can be used to treat a virally infected animal, such as a human. The compositions of the present invention are particularly useful in inhibiting the growth or replication of a virus, such as a retrovirus, in particular a human

004037873-102799

immunodeficiency virus, specifically HIV-1 and HIV-2. The compositions are useful in the therapeutic or prophylactic treatment of animals, such as humans, who are infected with a virus or who are at risk for viral infection, respectively. The compositions also can be used to treat objects or materials, such as medical equipment, supplies, or fluids, including biological fluids, such as blood, blood products, and tissues, to prevent viral infection of an animal, such as a human.

Such compositions also are useful to prevent sexual transmission of viral infections, e.g., HIV, which is the primary way in which the world's AIDS cases are contracted (Merson, 1993, supra).

Potential virucides used or being considered for use against sexual transmission of HIV are very limited; present agents in this category include nonoxynol-9 (Bird, AIDS 5, 791-796, 1991), gossypol and derivatives (Polsky et al., Contraception 39, 579-587, 1989; Lin, Antimicrob. Agents Chemother. 33, 2149-2151, 1989; and Royer, Pharmacol. Res. 24, 407-412, 1991), and gramicidin (Bourinbair, Life Sci./Pharmacol. Lett. 54, PL5-9, 1994; and Bourinbair et al., Contraception 49, 131-137, 1994). The method of prevention of sexual transmission of viral infection, e.g., HIV infection, in accordance with the present invention comprises vaginal, rectal, oral, penile or other topical treatment with an antiviral effective amount of a cyanovirin and/or cyanovirin conjugate, alone or in combination with another antiviral compound as described above.

Compositions for use in the prophylactic or therapeutic treatment methods of the present invention comprise one or more cyanovirin(s) or conjugate(s) thereof and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well-known to those who are skilled in the art, as are suitable methods of administration. The choice of carrier will be determined in part by the particular cyanovirin or

09407873 102799

conjugate thereof, as well as by the particular method used to administer the composition.

One skilled in the art will appreciate that various routes of administering a drug are available, and, although more than one route may be used to administer a particular drug, a particular route may provide a more immediate and more effective reaction than another route. Furthermore, one skilled in the art will appreciate that the particular pharmaceutical carrier employed will depend, in part, upon the particular cyanovirin or conjugate thereof employed, and the chosen route of administration. Accordingly, there is a wide variety of suitable formulations of the composition of the present invention.

Formulations suitable for oral administration can consist of liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or fruit juice; capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solid or granules; solutions or suspensions in an aqueous liquid; and oil-in-water emulsions or water-in-oil emulsions. Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers. Suitable formulations for oral delivery can also be incorporated into synthetic and natural polymeric microspheres, or other means to protect the agents of the present invention from degradation within the gastrointestinal tract (see, for example, Wallace et al., Science 260, 912-915, 1993).

The cyanovirins or conjugates thereof, alone or in combination with other antiviral compounds, can be made

09467873 102799

into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen and the like.

5 The cyanovirins or conjugates thereof, alone or in combinations with other antiviral compounds or absorption modulators, can be made into suitable formulations for transdermal application and absorption (Wallace et al., 1993, supra). Transdermal electroporation or
10 iontophoresis also can be used to promote and/or control the systemic delivery of the compounds and/or compositions of the present invention through the skin (e.g., see Theiss et al., Meth. Find. Exp. Clin. Pharmacol. 13, 353-359, 1991).

15 Formulations suitable for topical administration include lozenges comprising the active ingredient in a flavor, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and
20 acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier; as well as creams, emulsions, gels and the like containing, in addition to the active ingredient, such carriers as are known in the art.

25 Formulations for rectal administration can be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate. Formulations suitable for vaginal administration can be presented as pessaries, tampons, creams, gels, pastes,
30 foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate. Similarly, the active ingredient can be combined with a lubricant as a coating on a condom.

 Formulations suitable for parenteral administration
35 include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the

09427873 102795

formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

Formulations comprising a cyanovirin or cyanovirin conjugate suitable for virucidal (e.g., HIV) sterilization of inanimate objects, such as medical supplies or equipment, laboratory equipment and supplies, instruments, devices, and the like, can, for example, be selected or adapted as appropriate, by one skilled in the art, from any of the aforementioned compositions or formulations. Preferably, the cyanovirin is produced by recombinant DNA technology. The cyanovirin conjugate can be produced by recombinant DNA technology or by chemical coupling of a cyanovirin with an effector molecule as described above. Similarly, formulations suitable for ex vivo virucidal sterilization of blood, blood products, sperm, or other bodily products or tissues, or any other solution, suspension, emulsion or any other material which can be administered to a patient in a medical procedure, can be selected or adapted as appropriate by one skilled in the art, from any of the aforementioned compositions or formulations. However, suitable formulations for such ex vivo applications or for virucidal treatment of inanimate objects are by no means limited to any of the aforementioned formulations or compositions. One skilled in the art will appreciate that a suitable or appropriate formulation can be

selected, adapted or developed based upon the particular application at hand.

For *ex vivo* uses, such as virucidal treatments of inanimate objects or materials, blood or blood products, or tissues, the amount of cyanovirin, or conjugate or composition thereof, to be employed should be sufficient that any virus or virus-producing cells present will be rendered noninfectious or will be destroyed. For example, for HIV, this would require that the virus and/or the virus-producing cells be exposed to concentrations of cyanovirin-N in the range of 0.1-1000 nM. Similar considerations apply to *in vivo* applications. Therefore, the designation of "antiviral effective amount" is used generally to describe the amount of a particular cyanovirin, conjugate or composition thereof required for antiviral efficacy in any given application.

For *in vivo* uses, the dose of a cyanovirin, or conjugate or composition thereof, administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect a prophylactic or therapeutic response in the individual over a reasonable time frame. The dose used to achieve a desired antiviral concentration *in vivo* (e.g., 0.1-1000 nM) will be determined by the potency of the particular cyanovirin or conjugate employed, the severity of the disease state of infected individuals, as well as, in the case of systemic administration, the body weight and age of the infected individual. The size of the dose also will be determined by the existence of any adverse side effects that may accompany the particular cyanovirin, or conjugate or composition thereof, employed. It is always desirable, whenever possible, to keep adverse side effects to a minimum.

The dosage can be in unit dosage form, such as a tablet or capsule. The term "unit dosage form" as used herein refers to physically discrete units suitable as

unitary dosages for human and animal subjects, each unit containing a predetermined quantity of a cyanovirin or conjugate thereof, alone or in combination with other antiviral agents, calculated in an amount sufficient to
5 produce the desired effect in association with a pharmaceutically acceptable diluent, carrier, or vehicle.

The specifications for the unit dosage forms of the present invention depend on the particular cyanovirin, or conjugate or composition thereof, employed and the effect
10 to be achieved, as well as the pharmacodynamics associated with each cyanovirin, or conjugate or composition thereof, in the host. The dose administered should be an "antiviral effective amount" or an amount necessary to achieve an "effective level" in the
15 individual patient.

Since the "effective level" is used as the preferred endpoint for dosing, the actual dose and schedule can vary, depending upon interindividual differences in pharmacokinetics, drug distribution, and metabolism. The
20 "effective level" can be defined, for example, as the blood or tissue level (e.g., 0.1-1000 nM) desired in the patient that corresponds to a concentration of one or more cyanovirin or conjugate thereof, which inhibits a virus, such as HIV, in an assay known to predict for
25 clinical antiviral activity of chemical compounds and biological agents. The "effective level" for agents of the present invention also can vary when the cyanovirin, or conjugate or composition thereof, is used in combination with AZT or other known antiviral compounds or combinations thereof.
30

One skilled in the art can easily determine the appropriate dose, schedule, and method of administration for the exact formulation of the composition being used, in order to achieve the desired "effective concentration"
35 in the individual patient. One skilled in the art also can readily determine and use an appropriate indicator of the "effector concentration" of the compounds of the

09427873-102799

present invention by a direct (e.g., analytical chemical analysis) or indirect (e.g., with surrogate indicators such as p24 or RT) analysis of appropriate patient samples (e.g., blood and/or tissues).

5 In the treatment of some virally infected individuals, it can be desirable to utilize a "mega-dosing" regimen, wherein a large dose of the cyanovirin or conjugate thereof is administered, time is allowed for the drug to act, and then a suitable reagent is
10 administered to the individual to inactivate the drug.

The pharmaceutical composition can contain other pharmaceuticals, in conjunction with the cyanovirin or conjugate thereof, when used to therapeutically treat a viral infection, such as that which results in AIDS.
15 Representative examples of these additional pharmaceuticals include antiviral compounds, virucides, immunomodulators, immunostimulants, antibiotics and absorption enhancers. Exemplary antiviral compounds include AZT, ddI, ddC, gancyclovir, fluorinated
20 dideoxynucleosides, nonnucleoside analog compounds, such as nevirapine (Shih et al., PNAS 88, 9878-9882, 1991), TIBO derivatives, such as R82913 (White et al., Antiviral Res. 16, 257-266, 1991), BI-RJ-70 (Merigan, Am. J. Med. 90 (Suppl.4A), 8S-17S, 1991), michellamines (Boyd et al.,
25 J. Med. Chem. 37, 1740-1745, 1994) and calanolides (Kashman et al., J. Med. Chem. 35, 2735-2743, 1992), nonoxynol-9, gossypol and derivatives, and gramicidin (Bourinbair et al., 1994, supra). Exemplary immunomodulators and immunostimulants include various interleukins,
30 sCD4, cytokines, antibody preparations, blood transfusions, and cell transfusions. Exemplary antibiotics include antifungal agents, antibacterial agents, and anti-*Pneumocystitis carinii* agents. Exemplary absorption enhancers include bile salts and other
35 surfactants, saponins, cyclodextrins, and phospholipids (Davis, 1992, supra).

094873-102799

Administration of a cyanovirin or conjugate thereof with other anti-retroviral agents and particularly with known RT inhibitors, such as ddC, AZT, ddI, ddA, or other inhibitors that act against other HIV proteins, such as anti-TAT agents, is expected to inhibit most or all replicative stages of the viral life cycle. The dosages of ddC and AZT used in AIDS or ARC patients have been published. A virustatic range of ddC is generally between 0.05 μ M to 1.0 μ M. A range of about 0.005-0.25 mg/kg body weight is virustatic in most patients. The preliminary dose ranges for oral administration are somewhat broader, for example 0.001 to 0.25 mg/kg given in one or more doses at intervals of 2, 4, 6, 8, 12, etc. hours. Currently, 0.01 mg/kg body weight ddC given every 8 hrs is preferred. When given in combined therapy, the other antiviral compound, for example, can be given at the same time as the cyanovirin or conjugate thereof or the dosing can be staggered as desired. The two drugs also can be combined in a composition. Doses of each can be less when used in combination than when either is used alone.

It will also be appreciated by one skilled in the art that a DNA sequence of a cyanovirin or conjugate thereof of the present invention can be inserted *ex vivo* into mammalian cells previously removed from a given animal, in particular a human, host. Such cells can be employed to express the corresponding cyanovirin or conjugate *in vivo* after reintroduction into the host. Feasibility of such a therapeutic strategy to deliver a therapeutic amount of an agent in close proximity to the desired target cells and pathogens, i.e., virus, more particularly retrovirus, specifically HIV and its envelope glycoprotein gp120, has been demonstrated in studies with cells engineered *ex vivo* to express sCD4 (Morgan et al., 1994, supra). It is also possible that, as an alternative to *ex vivo* insertion of the DNA sequences of the present invention, such sequences can be

inserted into cells directly *in vivo*, such as by use of an appropriate viral vector. Such cells transfected *in vivo* are expected to produce antiviral amounts of cyanovirin or a conjugate thereof directly *in vivo*.

5 The present inventive cyanovirins, conjugates, compositions and methods are further described in the context of the following examples. These examples serve to illustrate further the present invention and are not intended to limit the scope of the invention.

10

EXAMPLES

Example 1

15 This example shows details of anti-HIV bioassay-guided isolation and elucidation of pure cyanovirin from aqueous extracts of the cultured cyanobacterium, *Nostoc ellipsosporum*.

20 The method described in Weislow et al. (1989, supra) was used to monitor and direct the isolation and purification process. Cyanobacterial culture conditions, media and classification were as described previously. (Patterson, J. Phycol. 27, 530-536, 1991). Briefly, the cellular mass from a unialgal strain of *Nostoc ellipsosporum* (culture Q68D170) was harvested by filtration, freeze-dried and extracted with MeOH-CH₂Cl₂ (1:1) followed by H₂O. Bioassay indicated that only the H₂O extract contained HIV-inhibitory activity. A solution of the aqueous extract (30 mg/ml) was treated by addition of an equal volume of ethanol (EtOH). The resulting 1:1 H₂O-EtOH solution was kept at -20°C for 15 hrs. Then, the solution was centrifuged to remove precipitated materials (presumably, high molecular weight biopolymers). The resulting HIV-inhibitory supernatant was evaporated, then fractionated by reverse-phase vacuum-liquid chromatography (Coll et al., J. Nat. Prod. 49, 934-936, 1986; and Pelletier et al., J. Nat. Prod. 49, 892-900, 1986) on wide-pore C₄ packing (300Å, BakerBond WP-C₄), and eluted with increasing concentrations of methanol (MeOH)

09467873-102799

in H₂O. Anti-HIV activity was concentrated in the material eluted with MeOH-H₂O (2:1). SDS-PAGE analysis of this fraction showed one main protein band, with a relative molecular mass (Mr) of approximately 10 kDa.

5 Final purification was achieved by repeated reverse-phase HPLC on 1.9 x 15 cm μ Bondapak C₁₈ (Waters Associates) columns eluted with a gradient of increasing concentration of acetonitrile in H₂O. The mobile phase contained 0.05% (v/v) TFA, pH=2. Eluted proteins and
10 peptides were detected by UV absorption at 206, 280 and 294 nm with a rapid spectral detector (Pharmacia LKB model 2140). Individual fractions were collected, pooled based on the UV chromatogram, and lyophilized. Pooled HPLC fractions were subjected to SDS-PAGE under reducing
15 conditions (Laemmli, Nature 227, 680-685, 1970), conventional amino acid analysis, and testing for anti-HIV activity.

Figure 1A is a graph of OD 206 nm versus time (min), which shows the μ Bondapak C₁₈ HPLC chromatogram of
20 nonreduced cyanovirin eluted with a linear CH₃CN/H₂O gradient (buffered with 0.05% TFA) from 28-38% CH₃CN. Figure 1D is a graph of OD 206 nm versus time (min), which shows the chromatogram of cyanovirin that was first reduced with β -mercaptoethanol and then separated under
25 identical HPLC conditions. HPLC fractions from the two runs were collected as indicated. 10% aliquots of each fraction were lyophilized, made up in 100 μ l 3:1 H₂O/DMSO and assessed for anti-HIV activity in the XTT assay. Figure 1B is a bar graph of maximum dilution for 50%
30 protection versus HPLC fraction, which illustrates the maximum dilution of each fraction that provided 50% protection from the cytopathic effects of HIV infection for the nonreduced cyanovirin HPLC fractions. Corresponding anti-HIV results for the HPLC fractions
35 from reduced cyanovirin are shown in Figure 1E, which is a bar graph of maximum dilution for 50% protection versus HPLC fraction. 20% aliquots of selected HPLC fractions

09427873-102799

were analyzed by SDS-PAGE. Results from the nonreduced HPLC fractions are shown in Figure 1C and those from the reduced HPLC fractions are shown in Figure 1F.

In the initial HPLC separation, using a linear
5 gradient from 30-50% CH₃CN, the anti-HIV activity coeluted with the principal UV-absorbing peak at approximately 33% CH₃CN. Fractions corresponding to the active peak were pooled and split into two aliquots.

Reinjection of the first aliquot under similar HPLC
10 conditions, but with a linear gradient from 28-38% CH₃CN, resolved the active material into two closely eluting peaks at 33.4 and 34.0% CH₃CN. The anti-HIV activity profile of the fractions collected during this HPLC run (as shown in Figure 1B) corresponded with the two UV
15 peaks (as shown in Figure 1A). SDS-PAGE of fractions collected under the individual peaks showed only a single protein band (as shown in Figure 1C).

The second aliquot from the original HPLC separation was reduced with β-mercaptoethanol prior to reinjection
20 on the HPLC. Using an identical 28-38% gradient, the reduced material gave one principal peak (as shown in Figure 1D) that eluted later in the run with 36.8% CH₃CN. Only a trace of anti-HIV activity was detected in the HPLC fractions from the reduced material (as shown in
25 Figure 1E).

The two closely eluting HPLC peaks of the nonreduced material (Figure 1A) gave only one identical band on SDS-PAGE (run under reducing conditions) (Figure 1C) and reduction with β-mercaptoethanol resulted in an HPLC peak
30 with a longer retention time than either of the nonreduced peaks (Figure 1F). This indicated that disulfides were present in the native protein. Amino acid analysis of the two active peaks showed they had virtually identical compositions. It is possible that
35 the two HPLC peaks resulted from *cis/trans* isomerism about a proline residue or from microheterogeneity in the protein sample that was not detected in either the amino

094427873-102799

acid analysis or during sequencing. The material collected as the two HIV-inhibitory peaks was combined for further analyses and was given the name cyanovirin-N.

5 Example 2

 This example illustrates synthesis of cyanovirin genes.

 The chemically deduced amino acid sequence of cyanovirin-N was back-translated to obtain a DNA coding
10 sequence. In order to facilitate initial production and purification of recombinant cyanovirin-N, a commercial expression vector (pFLAG-1, from International Biotechnologies, Inc., New Haven, CT), for which reagents were available for affinity purification and detection,
15 was selected. Appropriate restriction sites for ligation to pFLAG-1, and a stop codon, were included in the DNA sequence. Figure 2 is an example of a DNA sequence encoding a synthetic cyanovirin gene. This DNA sequence design couples the cyanovirin-N coding region to codons
20 for a "FLAG" octapeptide at the N-terminal end of cyanovirin, providing for production of a FLAG-cyanovirin fusion protein.

 A flowchart for synthesis of this DNA sequence is as follows:


25

39

5

10

15



The DNA sequence was synthesized as 13 overlapping,
complementary oligonucleotides and assembled to form the

double-stranded coding sequence. Oligonucleotide elements of the synthetic DNA coding sequence were synthesized using a dual-column nucleic acid synthesizer (Model 392, Applied Biosystems Inc., Foster City, CA).

5 Completed oligonucleotides were cleaved from the columns and deprotected by incubation overnight at 56°C in concentrated ammonium hydroxide. Prior to treatment with T4 polynucleotide kinase, 33-66 mers were drop-dialyzed against distilled water. The 13 oligonucleotide
10 preparations were individually purified by HPLC, and 10 nmole quantities of each were ligated with T4 DNA ligase into a 327 bp double-stranded DNA sequence. DNA was recovered and purified from the reaction buffer by phenol:chloroform extraction, ethanol precipitation, and
15 further washing with ethanol. Individual oligonucleotide preparations were pooled and boiled for 10 min to ensure denaturation. The temperature of the mixture was then reduced to 70°C for annealing of the complementary strands. After 20 min, the tube was cooled on ice and
20 2,000 units of T4 DNA ligase were added together with additional ligase buffer. Ligation was performed overnight at 16°C. DNA was recovered and purified from the ligation reaction mixture by phenol:chloroform extraction and ethanol precipitation and washing.

25 The purified, double-stranded synthetic DNA was then used as a template in a polymerase chain reaction (PCR). One μ l of the DNA solution obtained after purification of the ligation reaction mixture was used as a template. Thermal cycling was performed using a Perkin-Elmer
30 instrument. "Vent" thermostable DNA polymerase, restriction enzymes, T4 DNA ligase and polynucleotide kinase were obtained from New England Biolabs, Beverly, MA. Vent polymerase was selected for this application because of its claimed superiority in fidelity compared
35 to the usual Taq enzyme. The PCR reaction product was run on a 2% agarose gel in TBE buffer. The 327 bp construct was then cut from the gel and purified by

09427873 102799

electroelution. Because it was found to be relatively resistant to digestion with Hind III and Xho I restriction enzymes, it was initially cloned using the PCR-Script system (Stratagene). Digestion of a plasmid preparation from one of these clones yielded the coding sequence, which was then ligated into the multicloning site of the pFLAG-1 vector.

E. coli were transformed with the pFLAG-construct and recombinant clones were identified by analysis of restriction digests of plasmid DNA. Sequence analysis of one of these selected clones indicated that four bases deviated from the intended coding sequence. This included deletion of three bases coding for one of four cysteine residues contained in the protein and an alteration of the third base in the preceding codon (indicated by the boxes in Figure 2). In order to correct these "mutations," which presumably arose during the PCR amplification of the synthetic template, a double-stranded "patch" was synthesized, which could be ligated into restriction sites flanking the mutations. (these Bst XI and EspI sites are also indicated in Figure 2). The patch was applied and the repair was confirmed by DNA sequence analysis.

For preparation of a DNA sequence coding for native cyanovirin, the aforementioned FLAG-cyanovirin construct was subjected to site-directed mutagenesis to eliminate the codons for the FLAG octapeptide and, at the same time, to eliminate a unique Hind III restriction site. This procedure is illustrated in Figure 3, which illustrates a site-directed mutagenesis maneuver used to eliminate codons for a FLAG octapeptide and a Hind III restriction site from the sequence of Figure 2. A mutagenic oligonucleotide primer was synthesized, which included portions of the codons for the Omp secretory peptide and cyanovirin, but lacking the codons for the FLAG peptide. Annealing of this mutagenic primer, with creation of a DNA hairpin in the template strand, and


extension by DNA polymerase resulted in generation of new
plasmid DNA lacking both the FLAG codon sequence and the
Hind III site (refer to Figure 2 for details). Digestion
of plasmid DNA with Hind III resulted in linearization of
5 "wild-type" strands but not "mutant" strands. Since
transformation of *E. coli* occurs more efficiently with
circular DNA, clones could be readily selected which had
the revised coding sequence which specified production of
native cyanovirin-N directly behind the Omp secretory
10 peptide. DNA sequencing verified the presence of the
intended sequence. Site-directed mutagenesis reactions
were carried out using materials (polymerase, buffers,
etc.) obtained from Pharmacia Biotech, Inc., Piscataway,
NJ.

15

Example 3

This example illustrates expression of synthetic
cyanovirin genes.

As indicated in the following flowchart:




E. coli (strain DH5 α) were transformed (by electroporation) with the pFLAG-1 vector containing the coding sequence for the FLAG-cyanovirin-N fusion protein (see Figure 2 for details of the DNA sequence). Selected clones were seeded into small-scale shake flasks containing (LB) growth medium with 100 μ g/ml ampicillin and expanded by incubation at 37°C. Larger-scale Erlenmeyer flasks (0.5-3.0 liters) were then seeded and allowed to grow to a density of 0.5-0.7 OD₆₀₀ units. Expression of the FLAG-cyanovirin-N fusion protein was then induced by adding IPTG to a final concentration of 1.7 mM and continuing incubation at 30°C for 3-6 hrs. For harvesting of periplasmic proteins, bacteria were pelleted, washed, and then osmotically shocked by treatment with sucrose, followed by resuspension in distilled water. Periplasmic proteins were obtained by sedimenting the bacteria and then filtering the aqueous supernatant through Whatman paper. Crude periplasmic extracts showed both anti-HIV activity and presence of a FLAG-cyanovirin-N fusion protein by Western or spot-blotting.

The construct for native cyanovirin-N described in Example 2 was used to transform bacteria in the same manner as described above for the FLAG-cyanovirin-N fusion protein. Cloning, expansion, induction with IPTG, and harvesting were performed similarly. Crude periplasmic extracts showed strong anti-HIV activity on bioassay.

30 Example 4

This example illustrates purification of recombinant cyanovirin proteins.

Using an affinity column based on an anti-FLAG monoclonal antibody (International Biotechnologies, Inc., New Haven, CT), FLAG-cyanovirin-N fusion protein could be purified as follows:



The respective periplasmic extract, prepared as described in Example 3, was loaded onto 2-20 ml gravity columns containing affinity matrix and washed extensively with PBS containing Ca^{++} to remove contaminating proteins. Since the binding of the FLAG peptide to the antibody is Ca^{++} -dependent, fusion protein could be eluted by passage of EDTA through the column. Column fractions and wash volumes were monitored by spot-blot analysis using the same anti-FLAG antibody. Fractions containing fusion protein were then pooled, dialyzed extensively against distilled water, and lyophilized.

For purification of recombinant native cyanovirin-N, the corresponding periplasmic extract from Example 3 was subjected to step-gradient C_4 reverse-phase, vacuum-liquid chromatography to give three fractions: (1) eluted with 100% H_2O , (2) eluted with $MeOH-H_2O$ (2:1), and (3) eluted with 100% $MeOH$. The anti-HIV activity was concentrated

in fraction (2). Purification of the recombinant cyanovirin-N was performed by HPLC on a 1.9x15 cm μ Bondapak (Waters Associates) C_{18} column eluted with a gradient of increasing concentration of CH_3CN in H_2O (0.05% TFA, v/v in the mobile phase). A chromatogram of the final HPLC purification on a 1x10 cm (Cohensive Technologies, Inc.) C_4 column monitored at 280 nm is shown in Figure 4, which is typical HPLC chromatogram during the purification of a recombinant native cyanovirin. Gradient elution, 5 ml/min, from 100% H_2O to H_2O - CH_3CN (7:3) was carried out over 23 min with 0.05% TFA (v/v) in the mobile phase.

Example 5

This example shows anti-HIV activities of natural and recombinant cyanovirin-N and FLAG-cyanovirin-N.

Pure proteins were initially evaluated for antiviral activity using an XTT-tetrazolium anti-HIV assay described previously (Boyd, in AIDS, Etiology, Diagnosis, Treatment and Prevention, 1988, supra; Gustafson et al., J. Med. Chem. 35, 1978-1986, 1992; Weislow, 1989, supra; and Gulakowski, 1991, supra). The CEM-SS human lymphocytic target cell line used in all assays was maintained in RPMI 1650 medium (Gibco, Grand Island, NY), without phenol red, and was supplemented with 5% fetal bovine serum, 2 mM L-glutamine, and 50 μ g/ml gentamicin (complete medium).

Exponentially growing cells were pelleted and resuspended at a concentration of 2.0×10^5 cells/ml in complete medium. The Haitian variant of HIV, HTLV-III_{RF} (3.54×10^6 SFU/ml), was used throughout. Frozen virus stock solutions were thawed immediately before use and resuspended in complete medium to yield 1.2×10^5 SFU/ml. The appropriate amounts of the pure proteins for anti-HIV evaluations were dissolved in H_2O -DMSO (3:1), then diluted in complete medium to the desired initial concentration. All serial drug dilutions, reagent additions, and plate-

to-plate transfers were carried out with an automated Biomek 1000 Workstation (Beckman Instruments, Palo Alto, CA).

Figures 5A-5C are graphs of % control versus concentration (nm), which illustrate antiviral activities of native cyanovirin from *Nostoc ellipsosporum* (A), recombinant native (B), and recombinant FLAG-fusion (C) cyanovirins. The graphs show the effects of a range of concentrations of the respective cyanovirins upon CEM-SS cells infected with HIV-1 (●), as determined after 6 days in culture. Data points represent the percent of the respective uninfected, nondrug-treated control values. All three cyanovirins showed potent anti-HIV activity, with an EC₅₀ in the low nanomolar range and no significant evidence of direct cytotoxicity to the host cells at the highest tested concentrations (up to 1.2 μM).

As an example of a further demonstration of the anti-HIV activity of pure cyanovirin-N, a battery of interrelated anti-HIV assays was performed in individual wells of 96-well microtiter plates, using methods described in detail elsewhere (Gulakowski, 1991, supra). Briefly, the procedure was as follows. Cyanovirin solutions were serially diluted in complete medium and added to 96-well test plates. Uninfected CEM-SS cells were plated at a density of 1×10^4 cells in 50 μl of complete medium. Diluted HIV-1 was then added to appropriate wells in a volume of 50 μl to yield a multiplicity of infection of 0.6. Appropriate cell, virus, and drug controls were incorporated in each experiment. The final volume in each microtiter well was 200 μl. Quadruplicate wells were used for virus-infected cells. Plates were incubated at 37°C in an atmosphere containing 5% CO₂ for 4, 5, or 6 days.

Subsequently, aliquots of cell-free supernatant were removed from each well using the Biomek, and analyzed for reverse transcriptase activity, p24 antigen production, and synthesis of infectious virions as described

(Gulakowski, 1991, supra). Cellular growth or viability then was estimated on the remaining contents of each well using the XTT (Weislow et al., 1989, supra), BCECF (Rink et al., J. Cell Biol. 95, 189-196, 1982), and DAPI (McCaffrey et al., In Vitro Cell Develop. Biol. 24, 247-252, 1988) assays as described (Gulakowski et al., 1991, supra). To facilitate graphical displays and comparisons of data, the individual experimental assay results (of at least quadruplicate determinations of each) were averaged, and the mean values were used to calculate percentages in reference to the appropriate controls. Standard errors of the mean values used in these calculations typically averaged less than 10% of the respective mean values.

Figures 6A-6D are graphs of % control versus concentration (nm), which illustrate anti-HIV activity of a cyanovirin in a multiparameter assay format. Graphs 6A, 6B, and 6C show the effects of a range of concentrations of cyanovirin upon uninfected CEM-SS cells (O), and upon CEM-SS cells infected with HIV-1 (●), as determined after 6 days in culture. Graph 6A depicts the relative numbers of viable CEM-SS cells, as assessed by the BCECF assay. Graph 6B depicts the relative DNA contents of the respective cultures. Graph 6C depicts the relative numbers of viable CEM-SS cells, as assessed by the XTT assay. Graph 6D shows the effects of a range of concentrations of cyanovirin upon indices of infectious virus or viral replication as determined after 4 days in culture. These indices include viral reverse transcriptase (▲), viral core protein p24 (◆), and syncytium-forming units (■). In graphs 6A, 6B, and 6C, the data are represented as the percent of the uninfected, nondrug-treated control values. In graph 6D the data are represented as the percent of the infected, nondrug-treated control values.

As illustrated in Figure 6, cyanovirin-N was capable of complete inhibition of the cytopathic effects of HIV-1

09427873-102799

upon CEM-SS human lymphoblastoid target cells *in vitro*;
direct cytotoxicity of the protein upon the target cells
was not observed at the highest tested concentrations.
Cyanovirin-N also strikingly inhibited the production of
5 RT, p24, and SFU in HIV-1-infected CEM-SS cells within
these same inhibitory effective concentrations,
indicating that the protein halted viral replication.

The anti-HIV activity of the cyanovirins is
extremely resilient to harsh environmental challenges.
10 For example, unbuffered cyanovirin-N solutions withstood
repeated freeze-thaw cycles or dissolution in organic
solvents (up to 100% DMSO, MeOH, or CH₃CN) with no loss of
activity. Cyanovirin-N tolerated detergent (0.1% SDS),
high salt (6 M guanidine HCl) and heat treatment
15 (boiling, 10 min in H₂O) with no significant loss of HIV-
inhibitory activity. Reduction of the disulfides with β -
mercaptoethanol, followed immediately by C₁₈ HPLC
purification, drastically reduced the cytoprotective
activity of cyanovirin-N. However, solutions of reduced
20 cyanovirin-N regained anti-HIV inhibitory activity during
prolonged storage. When cyanovirin-N was reduced (β -
mercaptoethanol, 6M guanidine HCl, pH 8.0) but not put
through C₁₈ HPLC, and, instead, simply desalted,
reconstituted and assayed, it retained virtually full
25 activity.

Example 6

This example illustrates that the HIV viral envelope
gp120 is a principal molecular target of cyanovirin-N.

30 Initial experiments, employing the XTT-tetrazolium
assay (Weislow et al., 1989, supra), revealed that host
cells preincubated with cyanovirin (10 nM, 1 hr), then
centrifuged free of cyanovirin-N, retained normal
susceptibility to HIV infection; in contrast, the
35 infectivity of concentrated virus similarly pretreated,
then diluted to yield non-inhibitory concentrations of
cyanovirin-N, was essentially abolished. This indicated

that cyanovirin-N was acting directly upon the virus itself, i.e., acting as a direct "virucidal" agent to prevent viral infectivity even before it could enter the host cells. This was further confirmed in time-of-addition experiments, likewise employing the XTT-tetrazolium assay (Weislow, 1989, *supra*), which showed that, to afford maximum antiviral activity, cyanovirin-N had to be added to cells before or as soon as possible after addition of virus as shown in Figure 7, which is a graph of % uninfected control versus time of addition (hrs), which shows results of time-of-addition studies of a cyanovirin, showing anti-HIV activity in CEM-SS cells infected with HIV-1_{RF}. Introduction of cyanovirin (●) or ddC (■) (10 nM and 5 μ M concentrations, respectively) was delayed by various times after initial incubation, followed by 6 days incubation, then assay of cellular viability (linegraphs) and RT (open bars, inset). Points represent averages (\pm S.D.) of at least triplicate determinations. In marked contrast to the reverse transcriptase inhibitor ddC, delay of addition of cyanovirin-N by only 3 hrs resulted in little or no antiviral activity (Figure 7). The aforementioned results suggested that cyanovirin-N inhibited HIV infectivity by interruption of the initial interaction of the virus with the cell; this would, therefore, likely involve a direct interaction of cyanovirin-N with the viral gp120. This was confirmed by ultrafiltration experiments and dot-blot assays.

Ultrafiltration experiments were performed to determine if soluble gp120 and cyanovirin-N could bind directly, as assessed by inhibition of passage of cyanovirin-N through a 50 kDa-cutoff ultrafilter. Solutions of cyanovirin (30 μ g) in PBS were treated with various concentrations of gp120 for 1 hr at 37°C, then filtered through a 50 kDa-cutoff centrifugal ultrafilter (Amicon). After washing 3 times with PBS, filtrates were desalted with 3 kDa ultrafilters; retentates were

lyophilized, reconstituted in 100 μ l H₂O and assayed for anti-HIV activity.

Figure 8A is a graph of OD (450 nm) versus cyanovirin concentration (μ g/ml), which illustrates cyanovirin/gp120 interactions defining gp120 as a principal molecular target of cyanovirin. Free cyanovirin-N was readily eluted, as evidenced by complete recovery of cyanovirin-N bioactivity in the filtrate. In contrast, filtrates from cyanovirin-N solutions treated with gp120 revealed a concentration-dependent loss of filtrate bioactivity; moreover, the 50kDa filter retentates were all inactive, indicating that cyanovirin-N and soluble gp120 interacted directly to form a complex incapable of binding to gp120 of intact virus.

There was further evidence of a direct interaction of cyanovirin-N and gp120 in a PVDF membrane dot-blot assay. A PVDF membrane was spotted with 5 μ g CD4 (CD), 10 μ g aprotinin (AP), 10 μ g bovine globulin (BG), and decreasing amounts of cyanovirin; 6 μ g [1], 3 μ g [2], 1.5 μ g [3], 0.75 μ g [4], 0.38 μ g [5], 0.19 μ g [6], 0.09 μ g [7], and 0.05 μ g [8], then washed with PBST and visualized per manufacturer's recommendations. Figure 8B is a dot blot of binding of cyanovirin and a gp120-HRP conjugate (Invitrogen), which shows that cyanovirin-N specifically bound a horseradish peroxidase conjugate of gp120 (gp120-HRP) in a concentration-dependent manner.

All of the references cited herein are hereby incorporated in their entireties by reference.

While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations of the preferred compounds and methods may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications

encompassed within the spirit and scope of the invention
as defined by the following claims.

004283-10299
662201-6822460

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Boyd, Michael R.
Gustafson, Kirk R.
Shoemaker, Robert H.
McMahon, James B.
- (ii) TITLE OF INVENTION: ANTIVIRAL PROTEINS AND PEPTIDES, DNA
CODING SEQUENCES THEREFOR, AND USES THEREOF
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Leydig, Voit & Mayer, Ltd.
(B) STREET: Two Prudential Plaza, Suite 4900
(C) CITY: Chicago
(D) STATE: IL
(E) COUNTRY: U.S.A.
(F) ZIP: 60601-6780
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE: 27-APR-1995
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Larcher, Carol
(B) REGISTRATION NUMBER: 35243
(C) REFERENCE/DOCKET NUMBER: 61037
- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (312)616-5600
(B) TELEFAX: (312)616-5700

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 327 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 10..312
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CGATCGAAG CTT GGT AAA TTC TCC CAG ACC TGC TAC AAC TCC GCT ATC 48
Leu Gly Lys Phe Ser Gln Thr Cys Tyr Asn Ser Ala Ile
1 5 10

CAG GGT TCC GTT CTG ACC TCC ACC TGC GAA CGT ACC AAC GGT GGT TAC 96
Gln Gly Ser Val Leu Thr Ser Thr Cys Glu Arg Thr Asn Gly Gly Tyr
15 20 25

00427873-102799

AAC ACC TCC TCC ATC GAC CTG AAC TCC GTT ATC GAA AAC GTT GAC GGT 144
 Asn Thr Ser Ser Ile Asp Leu Asn Ser Val Ile Glu Asn Val Asp Gly
 30 35 40 45
 TCC CTG AAA TGG CAG CCG TCC AAC TTC ATC GAA ACC TGC CGT AAC ACC 192
 Ser Leu Lys Trp Gln Pro Ser Asn Phe Ile Glu Thr Cys Arg Asn Thr
 50 55 60
 CAG CTG GCT GGT TCC TCC GAA CTG GCT GCT GAA TGC AAA ACC CGT GCT 240
 Gln Leu Ala Gly Ser Ser Glu Leu Ala Ala Glu Cys Lys Thr Arg Ala
 65 70 75
 CAG CAG TTC GTT TCC ACC AAA ATC AAC CTG GAC GAC CAC ATC GCT AAC 288
 Gln Gln Phe Val Ser Thr Lys Ile Asn Leu Asp Asp His Ile Ala Asn
 80 85 90
 ATC GAC GGT ACC CTG AAA TAC GAA TAACTCGAGA TCGTA 327
 Ile Asp Gly Thr Leu Lys Tyr Glu
 95 100

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 101 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Leu Gly Lys Phe Ser Gln Thr Cys Tyr Asn Ser Ala Ile Gln Gly Ser
 1 5 10 15
 Val Leu Thr Ser Thr Cys Glu Arg Thr Asn Gly Gly Tyr Asn Thr Ser
 20 25 30
 Ser Ile Asp Leu Asn Ser Val Ile Glu Asn Val Asp Gly Ser Leu Lys
 35 40 45
 Trp Gln Pro Ser Asn Phe Ile Glu Thr Cys Arg Asn Thr Gln Leu Ala
 50 55 60
 Gly Ser Ser Glu Leu Ala Ala Glu Cys Lys Thr Arg Ala Gln Gln Phe
 65 70 75 80
 Val Ser Thr Lys Ile Asn Leu Asp Asp His Ile Ala Asn Ile Asp Gly
 85 90 95
 Thr Leu Lys Tyr Glu
 100

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 327 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..327

09427873-102799

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GAC TAC AAG GAC GAC GAT GAC AAG CTT GGT AAA TTC TCC CAG ACC TGC 48
 Asp Tyr Lys Asp Asp Asp Asp Lys Leu Gly Lys Phe Ser Gln Thr Cys
 1 5 10 15

TAC AAC TCC GCT ATC CAG GGT TCC GTT CTG ACC TCC ACC TGC GAA CGT 96
 Tyr Asn Ser Ala Ile Gln Gly Ser Val Leu Thr Ser Thr Cys Glu Arg
 20 25 30

ACC AAC GGT GGT TAC AAC ACC TCC TCC ATC GAC CTG AAC TCC GTT ATC
 144
 Thr Asn Gly Gly Tyr Asn Thr Ser Ser Ile Asp Leu Asn Ser Val Ile
 35 40 45

GAA AAC GTT GAC GGT TCC CTG AAA TGG CAG CCG TCC AAC TTC ATC GAA 192
 Glu Asn Val Asp Gly Ser Leu Lys Trp Gln Pro Ser Asn Phe Ile Glu
 50 55 60

ACC TGC CGT AAC ACC CAG CTG GCT GGT TCC TCC GAA CTG GCT GCT GAA 240
 Thr Cys Arg Asn Thr Gln Leu Ala Gly Ser Ser Glu Leu Ala Ala Glu
 65 70 75 80

TGC AAA ACC CGT GCT CAG CAG TTG GTT TCC ACC AAA ATC AAC CTG GAC 288
 Cys Lys Thr Arg Ala Gln Gln Phe Val Ser Thr Lys Ile Asn Leu Asp
 85 90 95

GAC CAC ATC GCT AAC ATC GAC GGT ACC CTG AAA TAC GAA 327
 Asp His Ile Ala Asn Ile Asp Gly Thr Leu Lys Tyr Glu
 100 105

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 109 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Asp Tyr Lys Asp Asp Asp Asp Lys Leu Gly Lys Phe Ser Gln Thr Cys
 1 5 10 15

Tyr Asn Ser Ala Ile Gln Gly Ser Val Leu Thr Ser Thr Cys Glu Arg
 20 25 30

Thr Asn Gly Gly Tyr Asn Thr Ser Ser Ile Asp Leu Asn Ser Val Ile
 35 40 45

Glu Asn Val Asp Gly Ser Leu Lys Trp Gln Pro Ser Asn Phe Ile Glu
 50 55 60

Thr Cys Arg Asn Thr Gln Leu Ala Gly Ser Ser Glu Leu Ala Ala Glu
 65 70 75 80

Cys Lys Thr Arg Ala Gln Gln Phe Val Ser Thr Lys Ile Asn Leu Asp
 85 90 95

Asp His Ile Ala Asn Ile Asp Gly Thr Leu Lys Tyr Glu
 100 105

00467873-102799

WHAT IS CLAIMED IS:

1. An isolated and purified antiviral protein or peptide from *Nostoc ellipsosporum*.

5

2. A method of obtaining the protein of claim 1, comprising (a) identifying an extract of *Nostoc ellipsosporum* containing antiviral activity, (b) optionally removing high molecular weight biopolymers from said extract, (c) antiviral bioassay-guided fractionating said extract to obtain a crude extract of said protein, and (d) purifying said crude extract by reverse-phase HPLC to obtain said protein.

3. An isolated and purified nucleic acid molecule which is selected from the group consisting of a nucleic acid molecule which encodes an amino acid sequence of SEQ ID NO:2, a nucleic acid molecule which encodes an amino acid sequence of SEQ ID NO:4, a nucleic acid molecule comprising a sequence of SEQ ID NO:1, a nucleic acid molecule comprising a sequence of SEQ ID NO:3, and a nucleic acid molecule that is substantially homologous to any one or more of the aforesaid nucleic acid sequences.

4. An isolated and purified nucleic acid molecule of claim 3 which comprises a nucleic acid sequence encoding at least nine contiguous amino acids of the amino acid sequence of SEQ ID NO:2, which nucleic acid molecule encodes a functional cyanovirin.

30

5. An isolated and purified nucleic acid molecule comprising a first nucleic acid sequence of claim 3 coupled to a second nucleic acid sequence coding for an effector protein.

35

6. An isolated and purified nucleic acid molecule comprising a first nucleic acid sequence of claim 4

coupled to a second nucleic acid sequence coding for an effector protein.

5 7. The nucleic acid molecule of claim 6, wherein said effector protein is selected from the group consisting of a toxin and an immunological reagent.

8. An isolated and purified protein encoded by the nucleic acid molecule of claim 3.

10

9. A protein conjugate comprising a protein of claim 8 coupled to an effector molecule.

15 10. The protein conjugate of claim 9, wherein said effector molecule targets HIV glycoprotein gp120.

11. The protein conjugate of claim 10, wherein said effector molecule is selected from the group consisting of a toxin and an immunological reagent.

20

12. A pharmaceutical composition comprising an antiviral effective amount of the protein of claim 8 and a pharmaceutically acceptable carrier therefor.

25 13. A vector which comprises the nucleic acid molecule of claim 3.

14. A host cell containing the vector of claim 13.

30 15. A method of producing the protein of claim 8, which method comprises expressing said protein in a host cell of claim 14.

35 16. A method of preventing the spread of viral infection comprising treating an inanimate object with an antiviral effective amount of the protein of claim 8.

09427873-102799

5

10

15

ABSTRACT

The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.

0942787-102288




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D

FLAG Octapeptide

Asp Tyr Lys Asp Asp Asp Lys Lys Leu Gly Lys Phe Ser Gln Thr Cys Tyr Asn Ser Ala

Hind III

5' -CGA TCG AG CTT GGT AAA TTC CAG ACC TGC TAC AAC TCC GCT
3' -GCT AGC TTC GAA CCA TTT AAG AGG GTC TGG ACG ATG TTG AGG CGA

Ile Gln Gly Ser Val Leu Thr Ser Thr Cys Glu Arg Thr Asn Gly Tyr Asn Thr Ser

ATC CAG GGT TCC GTT CTG ACC TCC ACC TGC GAA CGT ACC AAC GGT GGT TAC AAC ACC TCC
TAG GTC CCA AGG CAA GAC TGG AGG TGG ACG CTT GCA TGG TTT CCA CCA ATG TTG TGG AGG
Ser Ile Asp Leu Asn Ser Val Ile Glu Asn Val Asp Gly Ser Leu Lys Trp Gln Pro Ser

TCC ATC GAC CTG AAC TCC GTT ATC GAA AAC GTT GAC GGT TCC CTG AAA TGG CAG CCG TCC
AGG TAG CTG GAC TTG AGG CAA TAG CTT TTG CAA CTG CCA AGG GAC TTT ACC GTC GGC AGG
Asn Phe Ile Glu Thr Cys Arg Asn Thr Gln Leu Ala Gly Ser Ser Glu Leu Ala Ala Glu

Bst XI

AAC TTC ATC GAA ACC TGC CGT AAC ACC CAG CTG CT GGT TCC TCC GAA CTG GCT GCT GAA
TTG AAG TAG CTT TGG ACG GCA TTG TGG GTC GAC CGA CCA AGG AGG CTT GAC CGA CGA CTT
Cys Lys Thr Arg Ala Gln Gln Phe Val Ser Thr Lys Ile Asn Leu Asp Asp His Ile Ala

Esp I

TGC AAA ACC CGT GCT CAG CAG TTC GTT TCC ACC AAA ATC AAC CTG GAC CAC ATC GCT
ACG TTT TGG GCA CGA GT C GTC AAG CAA AGG TGG TTT TAG TTG GAC CTG CTG TAG CGA
Asn Ile Asp Gly Thr Leu Lys Tyr Glu

Xho I

AAC ATC GAC GGT ACC CTG AAA TAC GAA TAA CTC GAG ATC GTA-3'
TTG TAG CTG CCA TGG GAC TTT ATG CTT ATT GAG CTC TAG CAT-5'

FIG. 2




FIG. 3

66220T.E2B2460




FIG. 4




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D

66220T E282460

FIG. 7B




FIG. 7A




FIG. 8




FIG. 9




FIG. 10




FIG. 11

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Boyd, Michael R.
Gustafson, Kirk R.
Shoemaker, Robert H.
McMahon, James B.
- (ii) TITLE OF INVENTION: ANTIVIRAL PROTEINS AND PEPTIDES, DNA CODING SEQUENCES THEREFOR, AND USES THEREOF
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Leydig, Voit & Mayer, Ltd.
 - (B) STREET: Two Prudential Plaza, Suite 4900
 - (C) CITY: Chicago
 - (D) STATE: IL
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 60601-6780
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US
 - (B) FILING DATE: 27-APR-1995
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Larcher, Carol
 - (B) REGISTRATION NUMBER: 35243
 - (C) REFERENCE/DOCKET NUMBER: 61037
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (312) 616-5600
 - (B) TELEFAX: (312) 616-5700

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 327 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 10..312
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

| | |
|---|----|
| CGATCGAAG CTT GGT AAA TTC TCC CAG ACC TGC TAC AAC TCC GCT ATC | 48 |
| Leu Gly Lys Phe Ser Gln Thr Cys Tyr Asn Ser Ala Ile | |
| 1 5 10 | |
| CAG GGT TCC GTT CTG ACC TCC ACC TGC GAA CGT ACC AAC GGT GGT TAC | 96 |
| Gln Gly Ser Val Leu Thr Ser Thr Cys Glu Arg Thr Asn Gly Gly Tyr | |
| 15 20 25 | |

(2) INFORMATION FOR SEQ ID NO:2:

(A) LENGTH: 101 amino acids

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

(2) INFORMATION FOR SEQ ID NO:3:

(A) LENGTH: 327 base pairs

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ix) FEATURE:

(B) LOCATION: 1..327

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| GAC | TAC | AAG | GAC | GAC | GAT | GAC | AAG | CTT | GGT | AAA | TTC | TCC | CAG | ACC | TGC | 48 |
| Asp | Tyr | Lys | Asp | Asp | Asp | Asp | Lys | Leu | Gly | Lys | Phe | Ser | Gln | Thr | Cys | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | |
| | | | | | | | | | | | | | | | | |
| TAC | AAC | TCC | GCT | ATC | CAG | GGT | TCC | GTT | CTG | ACC | TCC | ACC | TGC | GAA | CGT | 96 |
| Tyr | Asn | Ser | Ala | Ile | Gln | Gly | Ser | Val | Leu | Thr | Ser | Thr | Cys | Glu | Arg | |
| | | | 20 | | | | | 25 | | | | | 30 | | | |
| | | | | | | | | | | | | | | | | |
| ACC | AAC | GGT | GGT | TAC | AAC | ACC | TCC | TCC | ATC | GAC | CTG | AAC | TCC | GTT | ATC | |
| 144 | | | | | | | | | | | | | | | | |
| Thr | Asn | Gly | Gly | Tyr | Asn | Thr | Ser | Ser | Ile | Asp | Leu | Asn | Ser | Val | Ile | |
| | | 35 | | | | | 40 | | | | | 45 | | | | |
| | | | | | | | | | | | | | | | | |
| GAA | AAC | GTT | GAC | GGT | TCC | CTG | AAA | TGG | CAG | CCG | TCC | AAC | TTC | ATC | GAA | 192 |
| Glu | Asn | Val | Asp | Gly | Ser | Leu | Lys | Trp | Gln | Pro | Ser | Asn | Phe | Ile | Glu | |
| | 50 | | | | | 55 | | | | | 60 | | | | | |
| | | | | | | | | | | | | | | | | |
| ACC | TGC | CGT | AAC | ACC | CAG | CTG | GCT | GGT | TCC | TCC | GAA | CTG | GCT | GCT | GAA | 240 |
| Thr | Cys | Arg | Asn | Thr | Gln | Leu | Ala | Gly | Ser | Ser | Glu | Leu | Ala | Ala | Glu | |
| 65 | | | | | 70 | | | | 75 | | | | | | 80 | |
| | | | | | | | | | | | | | | | | |
| TGC | AAA | ACC | CGT | GCT | CAG | CAG | TTC | GTT | TCC | ACC | AAA | ATC | AAC | CTG | GAC | 288 |
| Cys | Lys | Thr | Arg | Ala | Gln | Gln | Phe | Val | Ser | Thr | Lys | Ile | Asn | Leu | Asp | |
| | | | | 85 | | | | 90 | | | | | | 95 | | |
| | | | | | | | | | | | | | | | | |
| GAC | CAC | ATC | GCT | AAC | ATC | GAC | GGT | ACC | CTG | AAA | TAC | GAA | | | | 327 |
| Asp | His | Ile | Ala | Asn | Ile | Asp | Gly | Thr | Leu | Lys | Tyr | Glu | | | | |
| | | | 100 | | | | 105 | | | | | | | | | |

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 109 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Tyr | Lys | Asp | Asp | Asp | Asp | Lys | Leu | Gly | Lys | Phe | Ser | Gln | Thr | Cys |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| | | | | | | | | | | | | | | | |
| Tyr | Asn | Ser | Ala | Ile | Gln | Gly | Ser | Val | Leu | Thr | Ser | Thr | Cys | Glu | Arg |
| | | | 20 | | | | | 25 | | | | | 30 | | |
| | | | | | | | | | | | | | | | |
| Thr | Asn | Gly | Gly | Tyr | Asn | Thr | Ser | Ser | Ile | Asp | Leu | Asn | Ser | Val | Ile |
| | | 35 | | | | | 40 | | | | | 45 | | | |
| | | | | | | | | | | | | | | | |
| Glu | Asn | Val | Asp | Gly | Ser | Leu | Lys | Trp | Gln | Pro | Ser | Asn | Phe | Ile | Glu |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| | | | | | | | | | | | | | | | |
| Thr | Cys | Arg | Asn | Thr | Gln | Leu | Ala | Gly | Ser | Ser | Glu | Leu | Ala | Ala | Glu |
| 65 | | | | | 70 | | | | 75 | | | | | | 80 |
| | | | | | | | | | | | | | | | |
| Cys | Lys | Thr | Arg | Ala | Gln | Gln | Phe | Val | Ser | Thr | Lys | Ile | Asn | Leu | Asp |
| | | | | 85 | | | | 90 | | | | | | 95 | |
| | | | | | | | | | | | | | | | |
| Asp | His | Ile | Ala | Asn | Ile | Asp | Gly | Thr | Leu | Lys | Tyr | Glu | | | |
| | | | 100 | | | | 105 | | | | | | | | |

COMBINED DECLARATION AND POWER OF ATTORNEY

As below named inventor, I hereby declare that

This declaration is of the following type:

- ☐ original ☐ design ☐ supplemental
☐ national stage of PCT
☐ divisional ☒ continuation ☐ continuation-in-part

My residence, post office address, and citizenship are as stated below next to my name. I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHODS OF USING CYANOVIRINS TO INHIBIT VIRAL
INFECTION

the specification of which:

- ☒ is attached hereto.
☐ was filed on _____ as Serial No. _____ and was amended on _____ (if applicable).
☐ was filed by Express Mail No. _____ as Serial No. not known yet, and was amended on _____ (if applicable).
☐ was described and claimed in PCT International Application No. _____ filed on _____ and as amended under PCT Article 19 on _____ (if any).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

| COUNTRY | APPLICATION | DATE OF FILING (day,month,year) | PRIORITY CLAIMED UNDER 35 USC 119 | | |
|---------|-------------|------------------------------------|--------------------------------------|--|----|
| | | | YES | | NO |
| | | | YES | | NO |
| | | | YES | | NO |
| | | | YES | | NO |

I hereby claim the benefit pursuant to Title 35, United States Code, § 119(e) of the following United States provisional application(s):

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|--|--|
| In re Application of: | Group Art Unit: Unassigned |
| Boyd | Examiner: Unassigned |
| Continuation of Serial No. 08/969,378 | Date of Mailing of "Notice of Allowance And Base Issue Fee Due": Unassigned |
| Filed: October 27, 1999 | Issue Batch No. Unassigned |
| For: METHODS OF USING CYANOVIRINS TO INHIBIT VIRAL INFECTION | |

SUBMISSION OF FORMAL DRAWINGS

Assistant Commissioner for Patents
Washington, D.C. 20231


Attn: Official Draftsman

Dear Sir:

Applicant(s) enclose herewith 12 sheets of formal drawings and request(s) that the same be made of record in this application as a substitute for the informal drawings filed with the application.

The Assistant Commissioner is hereby authorized to charge any fees which may be required to Account No. 12-1216. A duplicate copy of this communication is enclosed for that purpose.

Respectfully submitted,



Carol Larcher, Reg. No. 35,243
One of the Attorneys for Applicant(s)
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: October 27, 1999

094283-1029
662207-6282460